KR20210100768A - Manufacturing method for gel effective components in melania snail and green tea for development of senior-friendly food - Google Patents
Manufacturing method for gel effective components in melania snail and green tea for development of senior-friendly food Download PDFInfo
- Publication number
- KR20210100768A KR20210100768A KR1020200014098A KR20200014098A KR20210100768A KR 20210100768 A KR20210100768 A KR 20210100768A KR 1020200014098 A KR1020200014098 A KR 1020200014098A KR 20200014098 A KR20200014098 A KR 20200014098A KR 20210100768 A KR20210100768 A KR 20210100768A
- Authority
- KR
- South Korea
- Prior art keywords
- green tea
- weight
- extract
- daseulgi
- gel
- Prior art date
Links
- 244000269722 Thea sinensis Species 0.000 title claims abstract description 62
- 235000009569 green tea Nutrition 0.000 title claims abstract description 58
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 14
- 241000237858 Gastropoda Species 0.000 title abstract 5
- 235000013305 food Nutrition 0.000 title description 18
- 238000011161 development Methods 0.000 title description 2
- 102000004190 Enzymes Human genes 0.000 claims abstract description 76
- 108090000790 Enzymes Proteins 0.000 claims abstract description 76
- 229940094952 green tea extract Drugs 0.000 claims abstract description 54
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 53
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000000203 mixture Substances 0.000 claims abstract description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 28
- 238000002156 mixing Methods 0.000 claims abstract description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 18
- 239000012153 distilled water Substances 0.000 claims abstract description 16
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 14
- 239000000679 carrageenan Substances 0.000 claims abstract description 14
- 229920001525 carrageenan Polymers 0.000 claims abstract description 14
- 229940113118 carrageenan Drugs 0.000 claims abstract description 14
- 235000010418 carrageenan Nutrition 0.000 claims abstract description 14
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims abstract description 14
- 150000003839 salts Chemical class 0.000 claims abstract description 13
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 12
- 239000000419 plant extract Substances 0.000 claims abstract description 10
- 239000008213 purified water Substances 0.000 claims abstract description 10
- 230000001954 sterilising effect Effects 0.000 claims abstract description 10
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 9
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 7
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 7
- 239000011718 vitamin C Substances 0.000 claims abstract description 7
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000011724 folic acid Substances 0.000 claims abstract description 6
- 229960000304 folic acid Drugs 0.000 claims abstract description 6
- 235000019152 folic acid Nutrition 0.000 claims abstract description 6
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 6
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 6
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims abstract description 5
- 239000001527 calcium lactate Substances 0.000 claims abstract description 5
- 229960002401 calcium lactate Drugs 0.000 claims abstract description 5
- 235000011086 calcium lactate Nutrition 0.000 claims abstract description 5
- 238000004806 packaging method and process Methods 0.000 claims abstract description 5
- 239000011833 salt mixture Substances 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 102000005158 Subtilisins Human genes 0.000 claims description 31
- 108010056079 Subtilisins Proteins 0.000 claims description 31
- 108010009355 microbial metalloproteinases Proteins 0.000 claims description 24
- 235000010804 Maranta arundinacea Nutrition 0.000 claims description 9
- 235000012419 Thalia geniculata Nutrition 0.000 claims description 9
- 241000245665 Taraxacum Species 0.000 claims description 7
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 4
- 229940067866 dandelion extract Drugs 0.000 claims description 3
- 235000020691 dandelion extract Nutrition 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000001845 taraxacum officinale leaf extract Substances 0.000 claims description 2
- 244000151018 Maranta arundinacea Species 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 abstract description 43
- 150000001413 amino acids Chemical class 0.000 abstract description 39
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 abstract description 31
- 239000002904 solvent Substances 0.000 abstract description 12
- 230000032683 aging Effects 0.000 abstract description 6
- 208000001076 sarcopenia Diseases 0.000 abstract description 6
- 235000013616 tea Nutrition 0.000 abstract description 4
- 230000004044 response Effects 0.000 abstract description 2
- 244000010000 Hovenia dulcis Species 0.000 abstract 2
- 235000008584 Hovenia dulcis Nutrition 0.000 abstract 2
- 241000533367 Cnidium officinale Species 0.000 abstract 1
- 244000046146 Pueraria lobata Species 0.000 abstract 1
- 235000010575 Pueraria lobata Nutrition 0.000 abstract 1
- 238000007789 sealing Methods 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 38
- 238000010998 test method Methods 0.000 description 37
- 229960003136 leucine Drugs 0.000 description 36
- 239000000284 extract Substances 0.000 description 33
- 238000000605 extraction Methods 0.000 description 24
- 235000012041 food component Nutrition 0.000 description 21
- 235000019640 taste Nutrition 0.000 description 17
- 238000012812 general test Methods 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 239000011575 calcium Substances 0.000 description 15
- 229910052791 calcium Inorganic materials 0.000 description 15
- 239000005417 food ingredient Substances 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 14
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 13
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 13
- 229960005069 calcium Drugs 0.000 description 13
- 230000001953 sensory effect Effects 0.000 description 13
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 12
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 12
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 12
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 12
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 12
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 12
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 12
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 12
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 12
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 12
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 12
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 12
- 229960003767 alanine Drugs 0.000 description 12
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 10
- 239000000306 component Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- 108010007119 flavourzyme Proteins 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 9
- 239000011734 sodium Substances 0.000 description 9
- 229910052708 sodium Inorganic materials 0.000 description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 8
- 244000145580 Thalia geniculata Species 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 229910052742 iron Inorganic materials 0.000 description 8
- 235000010755 mineral Nutrition 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- 235000015097 nutrients Nutrition 0.000 description 8
- 229910052700 potassium Inorganic materials 0.000 description 8
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
- 239000004472 Lysine Substances 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 229960000310 isoleucine Drugs 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 229960004295 valine Drugs 0.000 description 7
- GGTYBZJRPHEQDG-WCCKRBBISA-N (2s)-2,5-diaminopentanoic acid hydrochloride Chemical compound Cl.NCCC[C@H](N)C(O)=O GGTYBZJRPHEQDG-WCCKRBBISA-N 0.000 description 6
- QCHPKSFMDHPSNR-VKHMYHEASA-N (S)-3-aminoisobutyric acid Chemical compound [NH3+]C[C@H](C)C([O-])=O QCHPKSFMDHPSNR-VKHMYHEASA-N 0.000 description 6
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 6
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 6
- 239000004471 Glycine Substances 0.000 description 6
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 6
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 6
- 235000019766 L-Lysine Nutrition 0.000 description 6
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 6
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 6
- QWCKQJZIFLGMSD-VKHMYHEASA-N L-alpha-aminobutyric acid Chemical compound CC[C@H](N)C(O)=O QWCKQJZIFLGMSD-VKHMYHEASA-N 0.000 description 6
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 6
- 229930064664 L-arginine Natural products 0.000 description 6
- 235000014852 L-arginine Nutrition 0.000 description 6
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 6
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 6
- 239000004158 L-cystine Substances 0.000 description 6
- 235000019393 L-cystine Nutrition 0.000 description 6
- 229930182844 L-isoleucine Natural products 0.000 description 6
- 239000004395 L-leucine Substances 0.000 description 6
- 235000019454 L-leucine Nutrition 0.000 description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
- 229930195722 L-methionine Natural products 0.000 description 6
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 6
- BZQFBWGGLXLEPQ-REOHCLBHSA-L O-phosphonato-L-serine(2-) Chemical compound [O-]C(=O)[C@@H]([NH3+])COP([O-])([O-])=O BZQFBWGGLXLEPQ-REOHCLBHSA-L 0.000 description 6
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
- 239000004473 Threonine Substances 0.000 description 6
- 229960001230 asparagine Drugs 0.000 description 6
- 229960005261 aspartic acid Drugs 0.000 description 6
- 239000004202 carbamide Substances 0.000 description 6
- 229960002173 citrulline Drugs 0.000 description 6
- 229960003067 cystine Drugs 0.000 description 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 6
- 229960002989 glutamic acid Drugs 0.000 description 6
- 229960002885 histidine Drugs 0.000 description 6
- 229960004452 methionine Drugs 0.000 description 6
- 229960005190 phenylalanine Drugs 0.000 description 6
- 229960002429 proline Drugs 0.000 description 6
- 229960001153 serine Drugs 0.000 description 6
- 239000010802 sludge Substances 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 229960003080 taurine Drugs 0.000 description 6
- 229940026510 theanine Drugs 0.000 description 6
- 229960002898 threonine Drugs 0.000 description 6
- 239000011573 trace mineral Substances 0.000 description 6
- 235000013619 trace mineral Nutrition 0.000 description 6
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 6
- 229960004441 tyrosine Drugs 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 206010013911 Dysgeusia Diseases 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 150000005693 branched-chain amino acids Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 229910052802 copper Inorganic materials 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 235000019750 Crude protein Nutrition 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- 108700021154 Metallothionein 3 Proteins 0.000 description 2
- 102100028708 Metallothionein-3 Human genes 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 102000008934 Muscle Proteins Human genes 0.000 description 2
- 108010074084 Muscle Proteins Proteins 0.000 description 2
- 102000004472 Myostatin Human genes 0.000 description 2
- 108010056852 Myostatin Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000021028 berry Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- -1 furalin Chemical class 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000000663 muscle cell Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 235000002020 sage Nutrition 0.000 description 2
- 235000019600 saltiness Nutrition 0.000 description 2
- 235000019643 salty taste Nutrition 0.000 description 2
- 235000021003 saturated fats Nutrition 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 235000010692 trans-unsaturated fatty acids Nutrition 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 1
- BHDKTFQBRFWJKR-UHFFFAOYSA-N 2-hydroxy-5-sulfobenzoic acid;dihydrate Chemical compound O.O.OC(=O)C1=CC(S(O)(=O)=O)=CC=C1O BHDKTFQBRFWJKR-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 235000001270 Allium sibiricum Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008589 Choking Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 244000260524 Chrysanthemum balsamita Species 0.000 description 1
- 235000005633 Chrysanthemum balsamita Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 1
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 description 1
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WMBWREPUVVBILR-UHFFFAOYSA-N GCG Natural products C=1C(O)=C(O)C(O)=CC=1C1OC2=CC(O)=CC(O)=C2CC1OC(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 description 1
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 description 1
- 241000206572 Rhodophyta Species 0.000 description 1
- 241001306593 Semisulcospira Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000035508 accumulation Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 239000003809 bile pigment Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 231100000544 menstrual irregularity Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000004220 muscle function Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910017464 nitrogen compound Inorganic materials 0.000 description 1
- 150000002830 nitrogen compounds Chemical class 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/50—Molluscs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/06—Enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/262—Cellulose; Derivatives thereof, e.g. ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
- A23L3/44—Freeze-drying
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/214—Tea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/50—Concentrating, enriching or enhancing in functional factors
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 다슬기 효소 분해물에 녹차추출물을 용매로 첨가하여 아미노산 중 류신 함량을 높일 수 있어 고령화 시대에 대응하여 근감소증을 예방할 수 있는 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔을 제조하는 방법에 관한 것이다. The present invention is a method for producing an aging-friendly green tea gel using the enzyme decomposition product of Daseulgi and green tea extract, which can increase the leucine content in amino acids by adding green tea extract as a solvent to the enzyme decomposition product of Daseulgi and can prevent sarcopenia in response to the aging age is about
한국은 2018년 고령 사회로 진입하면서 고령친화식품의 산업이 급성장하고 있다. 2016년 국내 고령친화식품 산업규모는 8,554억원이며, ‘23년에는 1조 9,647억원으로 연평균 12.6%의 높은 성장률로 성장할 전망이다. 일본의 사례를 통해 확인하면 고령 사회 진입 후 건강기능식품 시장이 성장하였으므로 국내 건강기능식품 시장도 2026년까지 성장할 것으로 예상된다. As Korea entered an aging society in 2018, the age-friendly food industry is rapidly growing. In 2016, the size of the age-friendly food industry in Korea was 855.4 billion won, and it is expected to grow to 1.96 trillion won in '23 at a high annual growth rate of 12.6%. According to the case of Japan, since the health functional food market has grown after entering the aging society, the domestic health functional food market is also expected to grow by 2026.
고령친화식품에 가장 필요한 요건은 영양분, 소화, 저작 연하 용이 등의 순서이며, 노인에게 필요한 요소로 영양분(48.8%), 소화 잘되는 정도(26.5%), 치아와 미각 고려한 부드러움(20.3%) 등으로 나타났다. The most necessary requirements for age-friendly food are nutrients, digestion, and ease of chewing and swallowing, etc. appear.
고령 사회 선진국인 일본과 비교할 때, 우리나라의 고령 친화 식품 시장은 아직 미형성 단계로 판단되며 고령 사회의 문제점을 해결할 수 있는 고령 친화 식품 개발이 시급한 것으로 확인된다. Compared with Japan, which is an advanced country in an aging society, Korea's age-friendly food market is still in an undeveloped stage, and it is confirmed that there is an urgent need to develop age-friendly food that can solve the problems of an aging society.
다슬기는 연체동물 중복족목 다슬기과에 속하는 담수패로서 한국, 일본, 대만 등지에 널리 분포한다. 다슬기는 하천과 호수 등 물이 깊고 물살이 센 곳의 바위틈에 주로 서식하는데, 동의보감, 본초강목 등 동양의학서의 기록에 의하면 숙취해독에 좋고 당뇨예방과 눈을 맑게 하는데 효과가 있으며, 열독을 풀어주고 주독을 해소하며 소갈증(당뇨), 이질, 취질, 위암, 변비에 좋은 것으로 알려져 있다. 또한, 다슬기는 피를 맑게 하여 두통, 여성 어지러움증, 선혈증에 좋으며, 피부미용, 위장병에 특별한 효능이 있다.The mollusk is a freshwater clade belonging to the mollusk bipodidae, and it is widely distributed in Korea, Japan, and Taiwan. Daseulgi mainly lives in crevices of rocks in places with deep and strong currents such as rivers and lakes. It is known to be good for small thirst (diabetes), dysentery, choking, stomach cancer, and constipation. In addition, Daseulgi purifies the blood and is good for headache, dizziness, adenemia, and has special effects on skin care and gastrointestinal diseases.
다슬기는 요리하면 국물이 푸른빛을 띠는데 이는 혈액 속에 헤모글로빈을 만드는 구리 성분이 미네랄 형태로 함유된 것으로 간의 정화작용에 큰 역할을 하는 것으로 알려져 있다. 그리고, 최근에 와서 다슬기의 몇 가지 주요 구성성분이 밝혀졌는데, 뼈와 치아를 튼튼하게 하고 불면증을 완화하며 신경전달 기능 및 근육 운동을 원활하게 하여 부정맥을 방지하고 골다공증을 예방하는 수용성 칼슘과 신체각 세포들의 산소공급에 필요한 헤모글로빈의 구성성분을 다량 함유하고 있음이 밝혀졌다.When Daseulgi is cooked, the broth takes on a bluish color. It is known that the copper component that makes hemoglobin in the blood is contained in a mineral form and plays a big role in the purification of the liver. And, recently, several major components of sageum have been revealed. Water-soluble calcium and body angle that strengthen bones and teeth, relieve insomnia, smooth nerve transmission and muscle movement, prevent arrhythmias and prevent osteoporosis. It has been found that it contains a large amount of hemoglobin, a component necessary for oxygen supply to cells.
또한, 녹차의 경우 항산화 물질에 의해 혈전을 막아주고 혈압을 조절하여 심장 동맥을 지켜주며, 면역력 증진 효과가 있고 특히 65세 이상 노인 1만여명을 대상으로 연구한 결과 녹차를 매일 마신 사람은 노화가 진행되었을 때 적절하게 대처할 뿐만 아니라 잘 마시지 않는 사람들에 비해 다양한 일상생활을 더욱 노련하게 하는 것으로 발표되었다. 또한, 녹차는 항산화 물질인 EGCG가 함유되어 있어 두뇌 세포가 원활하게 성장하도록 하여 기억력과 학습력이 강화되는 것으로 밝혀졌다. In addition, in the case of green tea, antioxidants prevent blood clots, regulate blood pressure, protect heart arteries, and enhance immunity. It has been shown to not only respond appropriately when consumed, but also to be more proficient in a variety of daily activities compared to those who do not drink well. In addition, it has been found that green tea contains EGCG, an antioxidant, which helps brain cells to grow smoothly, enhancing memory and learning.
따라서 본 발명에서는 고령 친화 식품의 개발을 위해 다슬기와 녹차를 이용하여 노인을 위한 식품에 응용할 수 있도록 유효성분을 추출하는 효과적인 방법에 대해 제시하고자 한다. Therefore, the present invention intends to present an effective method for extracting active ingredients so that they can be applied to food for the elderly using green tea and dried sageum for the development of age-friendly food.
본 발명은 상기의 문제점을 해결하기 위해서 안출된 것으로서, 본 발명의 목적은 다슬기의 유효성분을 추출하는 효과적인 방법을 제시하는데 그 목적이 있다. The present invention has been devised to solve the above problems, and an object of the present invention is to present an effective method for extracting the active ingredient of Daseulgi.
또한, 본 발명은 다슬기와 녹차에서 추출된 추출물을 이용하여 노인을 위한 식품에 응용할 수 있는 유효 추출물을 제공하는데 그 목적이 있다. In addition, an object of the present invention is to provide an effective extract that can be applied to food for the elderly by using an extract extracted from Daseulgi and green tea.
또한, 본 발명의 목적은 다슬기의 생리활성 물질의 새로운 활성분야 도출 및 효소 분해기술을 통한 소재의 영역을 확장하는데 그 목적이 있다. In addition, it is an object of the present invention to expand the scope of materials through deriving a new active field of bioactive substances of Daseulgi and enzymatic decomposition technology.
발명이 해결하고자 하는 기술적 과제들은 이상에서 언급한 기술적 과제들로 제한되지 않으며, 언급되지 않은 또 다른 기술적 과제들은 아래의 기재로부터 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.The technical problems to be solved by the invention are not limited to the technical problems mentioned above, and other technical problems not mentioned will be clearly understood by those of ordinary skill in the art to which the present invention belongs from the description below. will be able
본 발명에 따른 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔 제조 방법은,The aging-friendly Daseulgi green tea gel manufacturing method using an enzyme decomposed product of Daseulgi and green tea extract according to the present invention,
정제수 70중량%, 칡 10중량%, 헛개줄기 10중량%, 헛개열매 5중량% 및 천궁5 중량%를 혼합하여 혼합식물추출액을 제조하는 제1단계;A first step of preparing a mixed plant extract by mixing 70% by weight of purified water, 10% by weight of arrowroot, 10% by weight of hutgae stem, 5% by weight of hutgae fruit, and 5% by weight of cheongung;
다슬기 과육, 증류수 및 녹차추출물을 혼합하여 농축다슬기녹차추출액을 제조하는 제2단계;A second step of preparing a concentrated green tea extract of dandelion extract by mixing the pulp of dandelion, distilled water, and green tea extract;
카라기난 57.25중량%에 정제염 0.1중량%를 혼합하는 제3단계;A third step of mixing 0.1% by weight of purified salt with 57.25% by weight of carrageenan;
상기 카라기난과 정제염 혼합물에 올리고당 15중량%, 상기 혼합식물추출액 15 중량%, 상기 농축다슬기녹차추출액 12중량%, 비타민C 0.2중량%, 엽산 0.1중량%, 젖산칼슘 0.1중량% 및 구연산 0.05중량%를 혼합하는 제4단계;To the carrageenan and refined salt mixture, 15% by weight of oligosaccharide, 15% by weight of the mixed plant extract, 12% by weight of the concentrated green tea extract, 0.2% by weight of vitamin C, 0.1% by weight of folic acid, 0.1% by weight of calcium lactate and 0.05% by weight of citric acid a fourth step of mixing;
상기 제4단계에서 혼합된 혼합물을 100℃에서 20분 동안 가열하여 다슬기녹차겔을 제조하는 제5단계;a fifth step of heating the mixture mixed in the fourth step at 100° C. for 20 minutes to prepare a green tea gel;
상기 다슬기녹차겔을 용기에 넣고 밀봉 포장하는 제6단계;A sixth step of putting the green tea gel in a container and sealingly packaging;
상기 밀봉 포장된 다슬기녹차겔을 멸균하는 제7단계;를 통해 제조되는 것을 특징으로 한다. It is characterized in that it is produced through the seventh step of sterilizing the sealed-packaged Daseulgi green tea gel.
상기 과제의 해결 수단에 의해, 본 발명은 다슬기와 녹차의 유효성분을 추출하는 효과적인 방법을 제시할 수 있다. By means of solving the above problems, the present invention can present an effective method of extracting the active ingredient of green tea leaves.
또한, 본 발명은 다슬기와 녹차에서 추출된 추출물을 이용하여 노인을 위한 식품에 응용할 수 있는 유효 추출물을 제공할 수 있다. In addition, the present invention can provide an effective extract that can be applied to food for the elderly by using the extract extracted from Daseulgi and green tea.
또한, 본 발명은 다슬기와 녹차의 혼합물에서 아미노산의 함량을 증가시킬 수 있는 추출방법을 제공할 수 있다. In addition, the present invention can provide an extraction method capable of increasing the content of amino acids in a mixture of green tea and dandelion.
또한, 본 발명은 근감소증 개선을 위해 근관세포(myotube) 분화, 근육 단백질 성장 억제인자(Myostatin) 감소 및 근육 세포 특이 효소인 류신의 활성을 증가시킬 수 있는 추출물을 제공할 수 있다. In addition, the present invention can provide an extract capable of increasing myotube differentiation, reduction of muscle protein growth inhibitory factor (Myostatin), and activity of muscle cell-specific enzyme leucine for improving sarcopenia.
도 1은 본 발명인 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔 제조 방법을 보여주는 순서도이다.
도 2는 다슬기 12시간 추출물의 효소별 루신의 함량(mg/mL)을 나타낸 그래프이다.
도 3은 다슬기 12시간 추출물의 혼합 효소별 루신의 함량(mg/mL)을 나타낸 그래프이다.
도 4는 분쇄다슬기의 용매별, 효소 함량별 루신의 함량(mg/mL)을 나타낸 그래프이다.
도 5는 분쇄다슬기 슬러지의 용매별, 효소 함량별 Luecine 함량(mg/mL)을 나타낸 그래프이다.
도 6은 다슬기 12시간 추출물의 효소 함량별 아미노산함량(mg/mL)을 나타낸 그래프이다.
도 7은 다슬기 24시간 추출물의 효소 함량별 아미노산함량(mg/mL)을 나타낸 그래프이다.
도 8(A)는 관능검사에 사용한 다슬기녹차겔 사진이고, 도 8(B)는 다슬기녹차겔을 전자렌지에 2분간 조리한 후 사용한 사진이다.
도 9는 관능검사 결과 중 각 속성별 기호도를 나타낸 결과 그래프이다.
도 10은 관능검사 결과 중 또 다른 각 속성별 기호도를 나타낸 결과 그래프이다. 1 is a flow chart showing a method for producing an aging-friendly green tea gel from Daseulgi Daseulgi using an enzyme decomposition product and green tea extract according to the present invention.
Figure 2 is a graph showing the content (mg / mL) of leucine for each enzyme of the 12-hour extract of Daseulgi.
Figure 3 is a graph showing the content (mg / mL) of leucine for each mixed enzyme of the 12-hour extract of Daseulgi.
Figure 4 is a graph showing the content (mg / mL) of leucine for each solvent and enzyme content of the crusher.
5 is a graph showing the luecine content (mg/mL) for each solvent and enzyme content of the crushed sludge.
6 is a graph showing the amino acid content (mg/mL) of each enzyme content of the 12-hour extract of Daseulgi.
Figure 7 is a graph showing the amino acid content (mg / mL) of each enzyme content of the 24 hours Daseulgi extract.
Fig. 8(A) is a photograph of green tea gel of dried sageum used in the sensory test, and FIG. 8(B) is a photograph of green tea gel used after cooking in a microwave oven for 2 minutes.
9 is a graph showing the degree of preference for each attribute among the sensory test results.
10 is a result graph showing the degree of preference for each attribute of another sensory test result.
본 명세서에서 사용되는 용어에 대해 간략히 설명하고, 본 발명에 대해 구체적으로 설명하기로 한다.Terms used in this specification will be briefly described, and the present invention will be described in detail.
본 발명에서 사용되는 용어는 본 발명에서의 기능을 고려하면서 가능한 현재 널리 사용되는 일반적인 용어들을 선택하였으나, 이는 당 분야에 종사하는 기술자의 의도 또는 판례, 새로운 기술의 출현 등에 따라 달라질 수 있다. 따라서 본 발명에서 사용되는 용어는 단순한 용어의 명칭이 아닌, 그 용어가 가지는 의미와 본 발명의 전반에 걸친 내용을 토대로 정의되어야 한다.The terms used in the present invention have been selected as currently widely used general terms as possible while considering the functions in the present invention, but these may vary depending on the intention or precedent of a person skilled in the art, the emergence of new technology, and the like. Therefore, the term used in the present invention should be defined based on the meaning of the term and the overall content of the present invention, rather than the name of a simple term.
명세서 전체에서 어떤 부분이 어떤 구성요소를 “포함”한다고 할 때, 이는 특별히 반대되는 기재가 없는 한 다른 구성요소를 제외하는 것이 아니라 다른 구성요소를 더 포함할 수 있음을 의미한다.In the entire specification, when a part “includes” a certain component, it means that other components may be further included, rather than excluding other components, unless otherwise stated.
아래에서는 첨부한 도면을 참고하여 본 발명의 실시예에 대하여 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있도록 상세히 설명한다. 그러나 본 발명은 여러 가지 상이한 형태로 구현될 수 있으며 여기에서 설명하는 실시예에 한정되지 않는다.Hereinafter, with reference to the accompanying drawings, embodiments of the present invention will be described in detail so that those of ordinary skill in the art can easily carry out the present invention. However, the present invention may be embodied in many different forms and is not limited to the embodiments described herein.
본 발명에 대한 해결하고자 하는 과제, 과제의 해결 수단, 발명의 효과를 포함한 구체적인 사항들은 다음에 기재할 실시 예 및 도면들에 포함되어 있다. 본 발명의 이점 및 특징, 그리고 그것들을 달성하는 방법은 첨부되는 도면과 함께 상세하게 후술되어 있는 실시 예들을 참조하면 명확해질 것이다.Specific details including the problem to be solved for the present invention, the means for solving the problem, and the effect of the invention are included in the embodiments and drawings to be described below. Advantages and features of the present invention, and a method for achieving them will become apparent with reference to the embodiments described below in detail in conjunction with the accompanying drawings.
본 발명인 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔 제조방법은 다슬기와 녹차에 포함된 유용 성분을 추출하고 생리활성 물질의 기능성을 확인하고자 한다. In the present invention, the method for producing an aging-friendly green tea gel using a decomposing product of Daseulgi Enzyme and green tea extract extracts useful ingredients contained in Daseulgi and green tea and aims to verify the functionality of physiologically active substances.
다슬기는 다수 포함된 올레산(oleic acid) 및 리놀레산(linoleic acid) 등을 포함한 필수지방산이 약 38.3%이고, 다슬기에 존재하는 미네랄은 대부분 K, Na, Ca, Mg, Cu, Fe, Zn 등임. 특히 Ca, Cu, Fe를 다량 함유하고 있다. 다슬기에 가장 많이 존재하는 칼슘의 경우, 비타민 D, 라이신과 아르기닌, 유당, 비타민 C와 결합을 통한 체내 흡수를 증진해주는 역할을 하며, 셀레늄의 경우 항암 작용 등에 효과가 있는 것으로 알려져, 칼슘보충제, 면역개선 등에 효과적으로 이용 가능할 것으로 기대된다. Daseulgi contains about 38.3% of essential fatty acids including oleic acid and linoleic acid, and most of the minerals present in Daseulgi are K, Na, Ca, Mg, Cu, Fe, Zn, etc. In particular, it contains a large amount of Ca, Cu and Fe. In the case of calcium, which is most abundant in Daseulgi, it plays a role in enhancing absorption in the body through binding with vitamin D, lysine, arginine, lactose, and vitamin C. It is expected that it can be effectively used for improvement, etc.
다슬기(Semisulcospira sp.)는 전통적으로 간장과 신장에 작용하여 갈증을 해소하고, 간의 열과 염증 및 위통, 소화불량, 만성간염, 간경화, 지방간에 효능이 있다고 알려져 있다. 다슬기 추출물에 관한 연구로는 항산화 작용, 사염화탄소 및 D-galactosamine에 의해 유발된 간 손상에 대해 보호 효과, 다슬기 추출물을 일정기간 섭식시키는 경우 간세포에 대한 보호 효과가 있으며, 숙취해소에도 효과가 있다는 연구가 진행된 바 있다. Semisulcospira sp. is traditionally known to be effective in relieving thirst by acting on the liver and kidneys, and being effective in liver heat and inflammation, stomach pain, indigestion, chronic hepatitis, cirrhosis of the liver, and fatty liver. As for the study on the extract, it has been reported that antioxidant activity, protective effect against liver damage caused by carbon tetrachloride and D-galactosamine, and that it has a protective effect on liver cells when consumed for a certain period of time, and that it is also effective in relieving a hangover. has been conducted
한편, BCAA (branched-chain amino acid)는 류신(Leucine), 이소류신(Isoleucine), 발린(Valine)으로 구성된 아미노산으로 주로 육체 피로와 강한 운동 시 근육세포를 유지, 면역증진, 근육단백질 분해 억제, 글리코겐 합성 및 축적에 관여하여 간 효소의 제어 활동 증진, 혈중 내 글루타티온(GSH) 상승을 통한 항산화 효과 등이 알려져 있다. 본 발명에 의한 다슬기의 효소분해로 단백질 중 다량이 류신으로 전환과 동시에 다른 BCAA 마이노산 함량 또한 증가함을 확인하였다. On the other hand, BCAA (branched-chain amino acid) is an amino acid composed of leucine, isoleucine, and valine. It is known that it is involved in synthesis and accumulation, enhancing the control activity of liver enzymes, and antioxidant effects by increasing glutathione (GSH) in the blood. It was confirmed that a large amount of protein was converted to leucine by enzymatic decomposition of Daseulgi according to the present invention, and the content of other BCAA minor acids was also increased.
상기 BCAA는 골격근에서 대사되고 간 대사를 거치지 않는다고 하여 간질환 환자의 영양공급에 사용이 권장되고 있고, 스트레스 등에 의한 간 손상시 간세포의 치료 및 재생하는 효능, 간섬유화 치료 및 예방에 사용되고 있어 본 발명을 이용하여 간기능 개선을 포함한 고령친화 식품 제조에 도움을 줄 것이라 판단된다. The BCAA is metabolized in skeletal muscle and does not undergo liver metabolism, so it is recommended to be used for nutritional supply of patients with liver disease. It is judged that it will help in the manufacture of age-friendly food including improvement of liver function by using
이하, 첨부된 도면을 참조하여 본 발명을 보다 상세히 설명하기로 한다.Hereinafter, the present invention will be described in more detail with reference to the accompanying drawings.
본 발명은 도 1에 나타난 바와 같이, 아래 단계에 의해 실행된다. As shown in FIG. 1 , the present invention is implemented by the following steps.
먼저, 제1단계(S100)는 정제수 70중량%, 칡 10중량%, 헛개줄기 10중량%, 헛개열매 5중량% 및 천궁5 중량%를 혼합하여 혼합식물추출액을 제조한다. First, in the first step (S100), 70% by weight of purified water, 10% by weight of arrowroot, 10% by weight of hutgae stem, 5% by weight of hutgae fruit, and 5% by weight of cheongung are mixed to prepare a mixed plant extract.
상기 칡은 퓨라린이 다량 함유되어 있다. 퓨라린은 암세포 증식 억제, 항산화, 당뇨, 심장질환 완화 등에 효과가 있는 것으로 알려져 있어, 예로부터 동양권에 서는 약재로 사용되어져 왔다. 퓨라린과 같은 이소플라본 계열인 다이드진(daidzin)이나 제니스틴(genistin)은 갱년기모델 동물실험 및 임상실험에서 골다공증, 고지혈증, 유방암 같은 갱년기 증후군에 효능이 있다고 보고되었다.The arrowroot contains a large amount of furalin. Furalin is known to be effective in inhibiting cancer cell proliferation, antioxidant, diabetes, and heart disease, and has been used as a medicine in the East since ancient times. Daidzin and genistin, which are isoflavones such as furalin, have been reported to be effective in menopausal syndromes such as osteoporosis, hyperlipidemia, and breast cancer in menopause model animal experiments and clinical trials.
상기 헛개줄기 및 상기 헛개열매는 담즙 색소가 몸 안에 필요 이상으로 생성되거나 몸 밖으로 배출되지 못할 경우 생기는 황달, 당뇨, 혈압 및 만성관절염 등에 효과가 있다. The hutgae stem and the hutgae fruit are effective in jaundice, diabetes, blood pressure and chronic arthritis, etc., which occur when bile pigments are produced in the body more than necessary or are not discharged out of the body.
상기 천궁은 주된 약능이 지통(止通)으로 빈혈증, 냉증, 월경불순 등 부인과 질환과 통증성 질환에 응용되고 있다. 또한, 천궁은 진정작용, 혈압강하작용, 혈관확장작용, 항균작용 및 항산화작용 등의 다양한 약리활성 연구결과가 보고되고 있다. The main medicinal ability of the cheongung is pain relief, so it is being applied to gynecological diseases and painful diseases such as anemia, poor circulation, and menstrual irregularities. In addition, various pharmacological activity research results such as sedative action, blood pressure lowering action, vasodilator action, antibacterial action, and antioxidant action have been reported.
상기 정제수 70중량%에 상기 칡 10중량% 미만으로 혼합하는 경우 상기 칡의 효능이 미미하고, 상기 칡을 10중량%를 초과하여 혼합하는 경우 상기 칡의 쓴맛으로 제조된 겔의 맛을 저해할 수 있으므로 상기 조건으로 실시하는 것이 바람직하다. If less than 10% by weight of the arrowroot is mixed with 70% by weight of the purified water, the efficacy of the arrowroot is insignificant, and when the arrowroot is mixed with more than 10% by weight, the bitter taste of the arrowroot may inhibit the taste of the gel Therefore, it is preferable to carry out under the above conditions.
또한, 상기 정제수 70중량%에 상기 헛개줄기 10중량% 미만으로 혼합하는 경우 상기 헛개줄기의 효능이 미미하고, 상기 헛개줄기 10중량%를 초과하여 혼합하는 경우 본 발명에 의해 제조된 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔의 류신 함량이 낮아질 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. In addition, when mixed with 70% by weight of the purified water at less than 10% by weight of the Huotgae stem, the efficacy of the Huotgae stem is insignificant, and when mixed in excess of 10% by weight of the Huotgae stem, the enzyme decomposition product of Daseulgi produced by the present invention and Since there is a fear that the leucine content of the aging-friendly green tea gel using green tea extract may be lowered, it is preferable to carry out under the above conditions.
또한, 상기 정제수 70중량%에 상기 헛개열매 5중량% 미만으로 혼합하는 경우 상기 헛개열매의 효능이 미미하고, 상기 헛개열매 5중량%를 초과하여 혼합하는 경우 본 발명에 의해 제조된 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔의 류신 함량이 낮아질 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. In addition, when mixed with 70% by weight of the purified water at less than 5% by weight of the hutgae berries, the efficacy of the hutgae berries is insignificant, and when mixed in excess of 5% by weight of the hutgae fruits, the decomposed enzyme produced by the present invention and Since there is a fear that the leucine content of the aging-friendly green tea gel using green tea extract may be lowered, it is preferable to carry out under the above conditions.
또한, 상기 정제수 70중량%에 상기 천궁 5중량% 미만으로 혼합하는 경우 상기 헛개열매의 효능이 미미하고, 상기 천궁 5중량%를 초과하여 혼합하는 경우 본 발명에 의해 제조된 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔의 류신 함량이 낮아질 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다.In addition, when mixed with 70% by weight of the purified water in an amount of less than 5% by weight of Chunkyung, the efficacy of the Heotgae fruit is insignificant, and when mixed in excess of 5% by weight of Chunkyung, the enzyme decomposition product and green tea extract prepared by the present invention Since there is a risk that the leucine content of the aging-friendly green tea gel using the
다음으로, 제2단계(S200)는 다슬기 과육, 증류수, 녹차추출물을 혼합하여 농축다슬기녹차추출액을 제조한다. 보다 구체적으로, 상기 제2단계(S200)는 아래 단계를 통해 실시되는 것이 바람직하다. Next, in the second step (S200), a concentrated green tea extract is prepared by mixing the pulp of dandelion, distilled water, and green tea extract. More specifically, the second step (S200) is preferably carried out through the following steps.
먼저, 제2-1단계(S210)는 상기 다슬기 과육 80중량%에 대하여 상기 증류수 17중량% 및 상기 녹차추출물 3중량%를 혼합한 혼합물에 알칼라아제(Alcalase), 플라보자임(Flavourzyme) 및 뉴트라제(Neutrase)을 혼합한 효소혼합물 0.01 중량부를 혼합한다. First, step 2-1 (S210) is a mixture of 17% by weight of distilled water and 3% by weight of the green tea extract with respect to 80% by weight of the pulp of the stalk of Alcalase, flavozyme and 0.01 parts by weight of an enzyme mixture mixed with Neutrase is mixed.
상기 다슬기는 깨끗한 물에 3시간 이상 담가 상기 다슬기 내부의 노폐물을 배출한 뒤 3회 이상 세척한다. The daseulgi is soaked in clean water for at least 3 hours to discharge the waste products inside the daseulgi, and then washed 3 times or more.
상기 녹차추출물은 상기 증류수에 녹차를 투입하여 80℃에서 1시간 동안 추출하여 제조한다.The green tea extract is prepared by adding green tea to the distilled water and extracting it at 80° C. for 1 hour.
상기 다슬기 과육 80 중량%에 대하여 상기 증류수 17 중량% 미만으로 혼합하는 경우 아래 제2-2단계(S220)에서 추출이 어려울 수 있고, 상기 증류수 17 중량%를 초과하여 혼합하는 경우 상기 다슬기의 효능이 미미할 수 있으므로 상기 조건으로 실시하는 것이 바람직하다. If less than 17% by weight of distilled water is mixed with respect to 80% by weight of the pulp of the dried sage, it may be difficult to extract in step 2-2 (S220) below, and when mixed with more than 17% by weight of the distilled water, the efficacy of the dried mulberry is increased Since it may be insignificant, it is preferable to carry out under the above conditions.
또한, 상기 다슬기 과육 80 중량%에 대하여 상기 녹차추출물 3 중량% 미만으로 혼합하는 경우 아래 제2-5단계(S250)에서 동결건조가 어려울 수 있고, 상기 녹차추출물 3 중량%를 초과하여 혼합하는 경우 상기 녹차의 효능이 미미할 수 있으므로 상기 조건으로 실시하는 것이 바람직하다. In addition, in the case of mixing less than 3% by weight of the green tea extract with respect to 80% by weight of the pulp of the dried sage, it may be difficult to freeze-drying in steps 2-5 (S250) below, and when mixing in excess of 3% by weight of the green tea extract Since the efficacy of the green tea may be insignificant, it is preferable to carry out under the above conditions.
상기 효소혼합물은 뉴트라제(Neutrase) 1 중량부에 대하여 알칼라아제(Alcalase) 1 중량부 및 플라보자임(Flavourzyme) 1 중량부를 혼합하는 것이 바람직하다. The enzyme mixture is preferably mixed with 1 part by weight of Alcalase and 1 part by weight of Flavozyme with respect to 1 part by weight of Neutrase.
상기 뉴트라제(Neutrase) 1 중량부에 대하여 상기 알칼라아제(Alcalase) 1 중량부 미만으로 혼합하는 경우 단백질 분해가 미미하여 류신의 생성률이 낮을 수 있고, 상기 알칼라아제(Alcalase) 1 중량부를 초과하여 혼합하는 경우 관능검사 시 전체적인 기호도가 낮을 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. When less than 1 part by weight of the Alcalase is mixed with respect to 1 part by weight of the Neutrase, the protein degradation may be insignificant and the production rate of leucine may be low, and the Alcalase (Alcalase) in excess of 1 part by weight In the case of mixing, it is preferable to carry out under the above conditions because there is a risk that the overall preference may be low during the sensory test.
상기 뉴트라제(Neutrase) 1 중량부에 대하여 상기 플라보자임(Flavourzyme) 1 중량부 미만으로 혼합하는 경우 단백질 분해가 미미하여 류신의 생성률이 낮을 수 있고, 상기 플라보자임(Flavourzyme) 1 중량부를 초과하여 혼합하는 경우 관능검사 시 전체적인 기호도가 낮을 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. When less than 1 part by weight of the flavozyme is mixed with respect to 1 part by weight of the neutrase, the protein degradation may be insignificant and the production rate of leucine may be low, and the flavourzyme may exceed 1 part by weight In the case of mixing, it is preferable to carry out under the above conditions because there is a risk that the overall preference may be low during the sensory test.
또한, 상기 효소혼합물은 농축다슬기녹차추출액 1중량부에 대하여 상기 뉴트라제(Neutrase), 알칼라아제(Alcalase) 및 플라보자임(Flavourzyme) 각각 0.1 중량부 혼합하는 것이 바람직하다. In addition, the enzyme mixture is preferably mixed with 0.1 parts by weight of each of the Neutrase, Alcalase and Flavozyme with respect to 1 part by weight of the concentrated green tea extract.
상기 농축다슬기녹차추출액 1중량부에 대하여 상기 효소혼합물 각각이 0.1 중량부 미만으로 혼합하는 경우 아미노산 중 류신의 함량이 낮아질 우려가 있고, 상기 효소혼합물 0.1 중량부를 초과하여 혼합하는 경우 또한 류신의 함량이 낮아질 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. When each of the enzyme mixtures is mixed in an amount of less than 0.1 parts by weight with respect to 1 part by weight of the concentrated green tea extract, there is a risk that the content of leucine in the amino acid is lowered. Since there is a possibility that it may become low, it is preferable to carry out under the said conditions.
다음으로, 제2-2단계(S220)는 상기 효소혼합물이 혼합된 혼합물을 진탕배양기(shaking incubator)에서 추출한다. 상기 녹차추출물에 상기 세척한 다슬기 과육과 상기 효소혼합물을 투입하여 추출한다. Next, in step 2-2 (S220), the mixture in which the enzyme mixture is mixed is extracted in a shaking incubator. The green tea extract is extracted by adding the washed pulp of sageumgi and the enzyme mixture.
상기 추출은 50 ℃에서 12시간 동안 1차 추출한 뒤 90℃에서 1시간 동안 2차 추출을 실시한다. 상기 1차 추출한 뒤 2차 추출을 시행하는 것은 1차 추출을 통해 류신의 함량을 증가시킨 뒤, 2차 추출을 통해 상기 다슬기 및 녹차의 유효성분을 추출하기 위함이다.The extraction is performed first at 50 °C for 12 hours, followed by secondary extraction at 90 °C for 1 hour. After the primary extraction, the secondary extraction is performed to increase the content of leucine through the primary extraction, and then extract the active ingredients of Daseulgi and green tea through secondary extraction.
상기 1차 추출이 50℃ 미만에서 실시하는 경우 류신의 함량이 낮아질 우려가 있고, 상기 1차 추출이 50℃를 초과하는 경우 상기 효소혼합물이 변질될 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. If the primary extraction is carried out at less than 50 ℃, there is a fear that the content of leucine may be lowered, if the primary extraction exceeds 50 ℃, there is a risk of deterioration of the enzyme mixture, it is preferable to carry out under the above conditions.
또한, 상기 1차 추출을 12시간 미만으로 실시하는 경우 류신의 함량이 낮아질 우려가 있고, 상기 1차 추출을 12시간 초과하여 실시하는 경우 류신 함량이 낮아질 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. In addition, if the primary extraction is carried out for less than 12 hours, there is a fear that the content of leucine may be lowered, and if the primary extraction is carried out for more than 12 hours, there is a fear that the leucine content may be lowered, so it is preferable to carry out under the above conditions. .
또한, 상기 2차 추출을 90℃ 미만으로 실시하는 경우 상기 다슬기 과육 및 녹차추출물의 유효성분이 추출되지 않을 수 있고, 상기 2차 추출을 90℃ 초과하여 실시하는 경우 상기 다슬기 과육 및 녹차추출물이 변질될 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. In addition, if the secondary extraction is carried out at less than 90 ℃, the active ingredients of the pulp and green tea extract may not be extracted. Since there is a concern, it is preferable to carry out under the above conditions.
또한, 상기 2차 추출을 1시간 미만으로 실시하는 경우 상기 다슬기 과육 및 녹차추출물의 유효성분이 추출되지 않을 수 있고, 상기 2차 추출을 1시간 초과하여 실시하는 경우 상기 다슬기 과육 및 녹차추출물이 변질될 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. In addition, if the secondary extraction is carried out for less than 1 hour, the active ingredients of the dried sageum fruit and green tea extract may not be extracted, and if the secondary extraction is carried out for more than 1 hour, the pulp and green tea extract may be altered. Since there is a concern, it is preferable to carry out under the above conditions.
다음으로, 제2-3단계(S230)는 상기 추출된 혼합물을 거름망으로 여과한다. 상기 거름망은 50 내지 100 메쉬의 크기로 여과하여 상기 추출된 혼합물의 여과를 효율적으로 실시한다. Next, in step 2-3 (S230), the extracted mixture is filtered through a sieve. The sieve is filtered to a size of 50 to 100 mesh to efficiently filter the extracted mixture.
다음으로, 제2-4단계(S240)는 상기 여과된 여과물을 감압농축기로 30℃에서 40rpm 이하 및 30mbar 압력으로 농축한다. 상기 농축은 40 BRIX까지 농축하는 것이 바람직하다. Next, in step 2-4 (S240), the filtered filtrate is concentrated at 30° C. with a reduced pressure concentrator at 40 rpm or less and a pressure of 30 mbar. The concentration is preferably up to 40 BRIX.
감압농축은 30℃ 미만으로 실시하는 경우 농축 속도가 느려진다는 문제점이 있고, 30℃를 초과하는 경우 추출물의 열변성 가능성 있을 수 있으므로 상기 조건으로 실시하는 것이 바람직 하다.Concentration under reduced pressure has a problem that the concentration rate becomes slow when it is carried out at less than 30°C, and when it exceeds 30°C, there may be a possibility of thermal denaturation of the extract, so it is preferable to carry out under the above conditions.
또한, 상기 감압농축은 40rpm 미만으로 실시하는 경우 추출물에 열을 빠르게 전달받지 못해 증발이 쉽게 일어나지 않는 문제점이 있고, 40rpm를 초과하는 경우 원심력으로 추출물이 넘칠 가능성이 있을 수 있으므로 상기 조건으로 실시하는 것이 바람직 하다.In addition, when the reduced pressure concentration is carried out at less than 40 rpm, there is a problem that evaporation does not occur easily because heat is not quickly transferred to the extract, and when it exceeds 40 rpm, there is a possibility that the extract may overflow by centrifugal force. desirable.
또한, 상기 감압농축은 30mbar 미만으로 실시하는 경우 추출물의 끓는점이 낮아지지 않아 농축에 시간이 걸리는 문제점이 있고, 30mbar 를 초과하는 경우 Vacuum pump가 가부하가 걸릴 가능성이 있을 수 있으므로 상기 조건으로 실시하는 것이 바람직 하다.In addition, when the reduced pressure concentration is carried out at less than 30 mbar, the boiling point of the extract is not lowered, so there is a problem that it takes time to concentrate, and when it exceeds 30 mbar, there is a possibility that the vacuum pump may take a temporary load. It is preferable to
다음으로, 제2-5단계(S250)는 상기 농축된 농축물을 90hPa 내지 100hPa의 압력 및 -80℃ 내지 -70℃의 온도로 동결건조한다. 상기 동결건조를 통해 분말을 제조한다. Next, in step 2-5 (S250), the concentrated concentrate is freeze-dried at a pressure of 90 hPa to 100 hPa and a temperature of -80°C to -70°C. A powder is prepared through the freeze-drying.
상기 농축물을 90hPa 미만의 압력으로 실시하는 경우 고체에서 기체로 승화 되는 시간이 걸리는 문제점이 있고, 100hPa를 초과하는 경우 Vaccum pump가 과부부하가 걸릴 가능성이 있을 수 있으므로 상기 조건으로 실시하는 것이 바람직 하다.When the concentration is carried out at a pressure of less than 90 hPa, there is a problem in that it takes time to sublimate from a solid to a gas, and when it exceeds 100 hPa, the Vaccum pump may be overloaded, so it is preferable to carry out under the above conditions. .
또한, 상기 농축물을 -80℃ 미만으로 실시하는 경우 용질이 용액에서 분리되지 못한 상태로 문제점이 있고, -70℃를 초과하는 경우 용액이 과포화되면서 용질의 결정체가 침전될 수 있을 가능성이 있을 수 있으므로 상기 조건으로 실시하는 것이 바람직 하다.In addition, when the concentrate is carried out at less than -80 ° C, there is a problem in that the solute cannot be separated from the solution, and when it exceeds -70 ° C, there is a possibility that crystals of the solute may be precipitated while the solution is supersaturated. Therefore, it is preferable to carry out under the above conditions.
다음으로, 제3단계(S300)는 카라기난 57.25 중량%에 정제염 0.1중량%를 혼합한다. Next, in the third step (S300), 0.1 wt% of purified salt is mixed with 57.25 wt% of carrageenan.
상기 카라기난은 홍조식물에서 채취되는 고무 모양의 물질로, 식품을 제조할 때 증점제로 사용된다. The carrageenan is a rubber-like material collected from red algae plants, and is used as a thickener when preparing food.
상기 정제염은 카라기난 용해시 뭉침 현상을 해소하기 위해 정제염과 혼합 후 첨가한다. 상기 정제염은 불순물을 최대한 걷어냈고 수분 함량이 적어 쉽게 짠맛을 내므로 첨가한다. The purified salt is added after mixing with the purified salt in order to eliminate agglomeration when dissolving carrageenan. The refined salt is added because the impurities are removed as much as possible and the water content is small, so that it easily gives a salty taste.
상기 카라기난 57.25 중량%에 정제염 0.1 중량% 미만으로 혼합하는 경우 상기 정제염의 혼합량이 낮아 상기 카라기난 용해가 미미하여 증점제 효과가 낮을 우려가 있고, 상기 정제염을 0.1중량% 초과하여 혼합하는 경우 불순물이 많아지거나 상기 정제염의 짠맛이 증가되어 식품에 혼합되었을 때 기호도가 낮아질 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. When mixed with 57.25% by weight of the carrageenan in an amount of less than 0.1% by weight of purified salt, the mixing amount of the purified salt is low, so that the dissolution of the carrageenan is insignificant and there is a concern that the thickener effect is low. It is preferable to carry out under the above conditions because the saltiness of the refined salt increases and there is a risk that the preference may be lowered when mixed with food.
다음으로, 제4단계(S400)는 상기 카라기난과 정제염 혼합물에 올리고당 15중량%, 상기 혼합식물추출액 15 중량%, 상기 농축다슬기녹차추출액 12중량%, 비타민C 0.2중량%, 엽산 0.1중량%, 젖산칼슘 0.1중량% 및 구연산 0.05중량%를 혼합한다. Next, the fourth step (S400) is 15% by weight of oligosaccharide in the carrageenan and purified salt mixture, 15% by weight of the mixed plant extract, 12% by weight of the concentrated Daseulgi green tea extract, 0.2% by weight of vitamin C, 0.1% by weight of folic acid, lactic acid 0.1% by weight of calcium and 0.05% by weight of citric acid are mixed.
상기 올리고당은 장내 균총을 개선하고 대장 내 pH를 저하하며 혈중 콜레스티롤 수치와 혈압을 낮추며 칼슘흡수를 돕는 등 설탕섭취로 인한 단점을 보완하기 위해 첨가한다.The oligosaccharide is added to improve the intestinal flora, lower the pH in the colon, lower blood cholesterol levels and blood pressure, and supplement the disadvantages caused by sugar intake, such as helping calcium absorption.
상기 비타민C는 근감소증이 우려되는 사람은 권장 섭취량보다 많은 단백질을 먹어야 하므로 단백질 합성 기능이 더욱 높아지는 효과를 볼 수 있는 장점이 있기 위해 첨가한다.The vitamin C is added to have the advantage of increasing the protein synthesis function because people who are concerned about sarcopenia should eat more protein than the recommended intake.
상기 엽산은 근감소증이 우려되는 사람은 권장 섭취량보다 많은 단백질을 먹어야 하므로 단백질 합성 기능이 더욱 높아지는 효과를 볼 수 있는 장점이 있기 위해 첨가한다.The folic acid is added in order to have the advantage of increasing the protein synthesis function because people who are concerned about sarcopenia should eat more protein than the recommended intake.
상기 젖산칼슘은 신경과 근육 기능 유지에 필요를 위해 첨가한다.The calcium lactate is added to maintain nerve and muscle function.
상기 구연산은 유기산으로서 유산소성 에너지 생산 필요를 위해 첨가한다.The citric acid is an organic acid and is added for aerobic energy production needs.
다음으로, 제5단계(S500)는 상기 제4단계(S400)에서 혼합된 혼합물을 100℃에서 20분 동안 가열하여 다슬기녹차겔을 제조한다. Next, in the fifth step (S500), the mixture mixed in the fourth step (S400) is heated at 100° C. for 20 minutes to prepare a dried green tea gel.
상기 제4단계(S400)에서 혼합된 혼합물을 100℃ 미만으로 혼합하는 경우 겔 형태로 제조되지 못할 우려가 있고, 100℃를 초과하여 혼합하는 경우 상기 제조된 다슬기녹차겔이 변성될 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. If the mixture mixed in the fourth step (S400) is mixed at less than 100°C, there is a fear that it cannot be prepared in a gel form, and if it is mixed at more than 100°C, there is a risk that the prepared Daseulgi green tea gel may be denatured. It is preferable to carry out under conditions.
또한, 상기 제4단계(S400)에서 혼합된 혼합물을 100℃에서 20분 미만으로 혼합하는 경우 겔 형태로 제조되지 못할 우려가 있고, 20분을 초과하여 혼합하는 경우 상기 제조된 다슬기녹차겔이 변성될 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. In addition, if the mixture mixed in the fourth step (S400) is mixed at 100° C. for less than 20 minutes, there is a fear that it cannot be prepared in a gel form, and if it is mixed for more than 20 minutes, the prepared Daseulgi green tea gel is denatured. It is preferable to carry out under the above conditions because there is a risk of becoming.
다음으로, 제6단계(S600)는 상기 다슬기녹차겔을 용기에 넣고 밀봉 포장한다. 레토르트 설비를 마련하여 상기 다슬기녹차죽을 용기에 넣고 밀봉 포장한다.Next, in the sixth step (S600), the dried green tea gel is put into a container and sealed. Prepare a retort facility, put the dried green tea porridge in a container, and seal it.
다음으로, 제7단계(S700)는 상기 밀봉 포장된 다슬기녹차겔을 멸균한다. 보다 구체적으로, 상기 제7단계(S700)는 121℃에서 30분 동안 실시하는 것이 바람직하다. Next, the seventh step (S700) sterilizes the sealed-packaged Daseulgi green tea gel. More specifically, the seventh step (S700) is preferably performed at 121 °C for 30 minutes.
상기 멸균은 121℃ 미만으로 실시하는 경우 멸균이 미미할 우려가 있고, 상기 멸균이 121℃를 초과하여 실시하는 경우 내부 다슬기녹차죽이 변질될 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. When the sterilization is carried out at less than 121 ℃, there is a fear that the sterilization is insignificant, and when the sterilization is carried out at more than 121 ℃, there is a risk of deterioration of the internal green tea porridge, so it is preferable to carry out under the above conditions.
또한, 상기 멸균은 30분 미만으로 실시하는 경우 멸균이 미미할 우려가 있고, 상기 멸균이 30분 초과하여 실시하는 경우 밀봉 포장이 변형될 우려가 있으므로 상기 조건으로 실시하는 것이 바람직하다. In addition, if the sterilization is carried out for less than 30 minutes, there is a fear that the sterilization is insignificant, and if the sterilization is carried out for more than 30 minutes, the sealed packaging may be deformed, so it is preferable to carry out under the above conditions.
아래는 본 발명에 의해 제조된 실험예 및 실시예를 나타내고자 한다. Below, the experimental examples and examples prepared by the present invention are shown.
가) 다슬기 추출 방법 및 효소 선정을 위한 예비실험A) Preliminary experiment for extraction method and enzyme selection
(1) 아미노산 중 류신 함량을 더 높일 수 있는 방법을 모색하기 위해 예비실험을 진행함(1) Preliminary experiments were conducted to find a way to further increase the content of leucine among amino acids.
(2) 다슬기 과육 250 g에 대하여 2배수의 용매(녹차추출물)를 첨가하여 Shaking Incubator(Shaking Incubator IS-971R, Lab. Companion, Jeio Tech, Korea)에서 추출함(2) Extracted in a Shaking Incubator (Shaking Incubator IS-971R, Lab. Companion, Jeio Tech, Korea) by adding twice the amount of solvent (green tea extract) to 250 g of the pulp
(3) 효소는 Alcalase 2.4L, Flavourzyme 500MG, Neutrase 0.8L를 혼합하여 사용하였음(3) The enzyme was used by mixing Alcalase 2.4L, Flavorzyme 500MG, and Neutrase 0.8L.
(4) 혼합한 효소가 충분히 반응할 수 있게 50 ℃에서 12시간, 24시간동안 추출한 후 90 ℃에서 1시간 추출하였음(4) Extracted at 50 °C for 12 hours and 24 hours so that the mixed enzymes can react sufficiently, and then extracted at 90 °C for 1 hour.
(5) 추출물은 거름망으로 여과하였음(5) The extract was filtered through a sieve
나) 분쇄 다슬기와 슬러지의 용매 차이에 따른 아미노산 성분 분석B) Analysis of amino acid components according to the difference in solvents between crushed shreds and sludge
(1) 다슬기 100 g에 대하여 2배수의 용매인 녹차추출물 200 g을 첨가하여 Shaking Incubator(Shaking Incubator IS-971R, Lab. Companion, Jeio Tech, Korea)에서 추출함(1) 200 g of green tea extract, which is twice the solvent, was added to 100 g of Daseulgi and extracted in a Shaking Incubator (Shaking Incubator IS-971R, Lab. Companion, Jeio Tech, Korea)
(2) 2배수의 용매인 녹차추출물 200 g을 대신하여 녹찻잎 2 g과 증류수 200 mL를 각각 첨가하여 Shaking Incubator(Shaking Incubator IS-971R, Lab. Companion, Jeio Tech, Korea)에서 추출함(2) Extracted in a Shaking Incubator (Shaking Incubator IS-971R, Lab. Companion, Jeio Tech, Korea) by adding 2 g of green tea leaves and 200 mL of distilled water, respectively, in place of 200 g of green tea extract, which is a solvent for doubling.
(3) 효소는 예비실험 결과를 토대로 Alcalase 2.4L, Flavourzyme 500MG, Neutrase 0.8L 세가지를 각 0.5 %, 1 % 씩 혼합하였음(3) Based on the results of the preliminary experiment, three enzymes were mixed with Alcalase 2.4L, Flavorzyme 500MG, and Neutrase 0.8L at 0.5% and 1% respectively.
(4) 혼합한 효소가 충분히 반응할 수 있게 50 ℃에서 12시간, 24시간동안 추출한 후 90 ℃에서 1시간 추출하였음(4) Extracted at 50 °C for 12 hours and 24 hours so that the mixed enzymes can react sufficiently, and then extracted at 90 °C for 1 hour.
(5) 추출물은 거름망으로 여과하였음(5) The extract was filtered through a sieve
(6) 거름망에 여과 된 슬러지를 회수하여 추출물과 동일하게 실험에 사용하였음(6) The sludge filtered through the sieve was recovered and used in the same experiment as the extract.
다) 다슬기 추출 방법 선정C) Selection of extract method
(1) 아미노산 중 류신 함량을 더 높일 수 있는 방법으로 표준화 실험을 수행함(1) A standardization experiment was performed in a way to further increase the leucine content among amino acids.
(2) 다슬기 과육 50 g에 대하여 10배수의 용매(증류수)와 녹차추출물 1%를 첨가하여 Shaking Incubator(Shaking Incubator IS-971R, Lab. Companion, Jeio Tech, Korea)에서 추출함(2) Extracted in a Shaking Incubator (Shaking Incubator IS-971R, Lab. Companion, Jeio Tech, Korea) by adding 10 times the amount of solvent (distilled water) and 1% of green tea extract to 50 g of the pulp
(3) 효소는 Alcalase 2.4L, Flavourzyme 500MG, Neutrase 0.8L를 혼합하여 사용하였음(3) The enzyme was used by mixing Alcalase 2.4L, Flavorzyme 500MG, and Neutrase 0.8L.
(4) 혼합한 효소의 양을 분해물질 대비 0.3%에서 1%, 2%, 3%로 늘렸으며, 늘어난 효소가 충분히 반응할 수 있게 50 ℃에서 12시간, 24시간동안 추출한 후 90℃에서 1시간 추출하였음(4) The amount of the mixed enzyme was increased from 0.3% to 1%, 2%, and 3% compared to the decomposed material, and after extraction at 50 ° C for 12 hours and 24 hours, 1 at 90 ° C to allow the increased enzyme to react sufficiently. time was extracted
(5) 추출물은 거름망으로 여과하였음(5) The extract was filtered through a sieve
아래는 앞서 기재된 실험예 및 실시예를 이용한 아미노산 함량 실험 방법을 나타내고, 본 발명에 의해 제조된 다슬기 녹차겔의 영양성분을 분석하는 방법을 나타내고자 한다. The following shows the amino acid content test method using the experimental examples and examples described above, and intends to show the method for analyzing the nutritional components of the Daseulgi green tea gel prepared by the present invention.
가) 아미노산 함량A) Amino acid content
(1) 시료 0.3 g에 증류수 10 mL을 첨가하여 Shaking Incubator(Shaking Incubator SI-600R, Lab. Companion, Jeio Tech, Korea)에 넣고 200 rpm으로 24시간동안 방치함(1) Add 10 mL of distilled water to 0.3 g of sample, put it in a Shaking Incubator (Shaking Incubator SI-600R, Lab. Companion, Jeio Tech, Korea), and leave it at 200 rpm for 24 hours.
(2) 10%의 5-Sulfosalicylic acid dihydrate 1 mL를 첨가한 후 4 ℃ 냉장고에서 24시간 동안 방치하여 단백질을 침전시킴(2) After adding 1 mL of 10% 5-Sulfosalicylic acid dihydrate, leave it in the refrigerator at 4 ℃ for 24 hours to precipitate the protein.
(3) 4,000 rpm으로 5분간 원심분리하여 상층액을 40 ℃이하에서 감압농축기(Rotary evporator, EYELA N-1100V-W, JAPAN)를 이용하여 농축 시킨 후 sample dilution buffer를 5 mL 첨가하여 용해함(3) After centrifugation at 4,000 rpm for 5 minutes, the supernatant was concentrated at 40 ℃ or less using a vacuum concentrator (Rotary evporator, EYELA N-1100V-W, JAPAN), and then 5 mL of sample dilution buffer was added and dissolved.
(4) 0.45 Membrance filter로 여과하여 120 uL를 아미노산분석기(Sykam S7130 Aminoacid reagent organiger, Germany)로 분석하였고, UV/VIS detector 400 nm(1.00 AU)와 570 nm(1.00 AU)로 검출함(4) Filtration with a 0.45 membrane filter, 120 uL was analyzed with an amino acid analyzer (Sykam S7130 Aminoacid reagent organiger, Germany), and UV/VIS
나) 다슬기 녹차겔, 영양성분 분석B) Daseulgi Green Tea Gel, Nutritional Analysis
영양성분은 식품공전(XX 개정)에 의거하여 분석하였음. Nutritional components were analyzed in accordance with the Food Codex (XX revision).
(1) 열량 : 식품공전 제8.일반시험법, 2.식품성분시험법 2.1일반성분시험법 2.1.6열량의 계산(1) Calorie:
(2) 탄수화물 : 제8.일반시험법, 2.식품성분시험법 2.1일반성분시험법 2.1.4 탄수화물(2) Carbohydrates:
(3) 수분 : 제8.일반시험법, 2.식품성분시험법 2.1일반성분시험법 2.1.1수분. 2.1.1.1건조감량법(3) Moisture:
(4) 회분 : 제8.일반시험법, 2.식품성분시험법 2.1일반성분시험법 2.1.2회분(4) Ash:
(5) 조단백질 : 제8.일반시험법, 2.식품성분시험법 2.1.3질소화합물 2.1.3.1총질소 및 조단백질(5) Crude protein:
(6) 조지방 : 제8.일반시험법, 2.식품성분시험법 2.1일반성분시험법 2.1.5지질 2.1.5.1조지방 (6) Crude fat:
(7) 트랜스지방 : 제8.일반시험법, 2.식품성분시험법 2.1일반성분시험법 2.1.6열량의 계산(7) Trans fat:
(8) 포화지방 : 제8.일반시험법, 2. 식품성분시험법 2.1일반성분시험법 2.1.5지질 2.1.5.4 지방산 제2법(8) Saturated fat:
(9) 당류 : 제8.일반시험법, 2. 식품성분시험법 2.1일반성분시험법 2.1.4탄수화물 2.1.4.1당류 2.1.4.1.4기기분석법에 의한 당류의 정량(9) Sugar:
(10) 나트륨 : 제8.일반시험법, 2. 식품성분시험법 2.2미량영양성분시험법 2.2.1무기질 2.2.1.6나트륨(10) Sodium:
(11) 콜레스테롤 : 제8.일반시험법, 2.식품성분시험법 2.1일반성분시험법 2.1.5지질 2.1.5.5콜레스테롤(11) Cholesterol:
다) 미량원소 분석C) Trace element analysis
(1) 칼슘 : 제8.일반시험법, 2.식품성분시험법 2.2미량영양성분시험법 2.2.1무기질 2.2.1.2칼슘(1) Calcium:
(2) 인 : 제8.일반시험법, 2.식품성분시험법 2.2미량영양성분시험법 2.2.1무기질 2.2.1.3인(2) Phosphorus:
(3) 철 : 제8.일반시험법, 2.식품성분시험법 2.2미량영양성분시험법 2.2.1무기질 2.2.1.4철(3) Iron:
(4) 나트륨 : 제8.일반시험법, 2.식품성분시험법 2.2미량영양성분시험법 2.2.1무기질 2.2.1.6나트륨(4) Sodium:
(5) 칼륨 : 제8.일반시험법, 2.식품성분시험법 2.2미량영양성분시험법 2.2.1무기질 2.2.1.7칼륨(5) Potassium:
아래는 앞서 기술한 아미노산 함량 실험방법을 이용하여 가) 다슬기 추출 방법 및 효소 선정을 위한 예비실험 결과를 나타내었다. The following shows the results of the preliminary experiments for a) extracting Daseulgi and enzyme selection using the amino acid content test method described above.
[표 1]은 다슬기 12시간 추출물의 효소별 아미노산함량(mg/mL) 결과이다. 또한, 도 2는 [표 1]에 나타난 아미노산 중 류신의 함량을 그래프로 나타내었다. [Table 1] shows the results of the amino acid content (mg/mL) of each enzyme of the 12-hour Daseulgi extract. In addition, Figure 2 is a graph showing the content of leucine among the amino acids shown in [Table 1].
[표 2]는 다슬기 12시간 추출물의 혼합 효소별 아미노산함량(mg/mL) 결과이다. 또한, 도 3은 [표 2]에 나타난 아미노산 중 류신의 함량을 그래프로 나타내었다. [Table 2] shows the results of amino acid content (mg/mL) for each enzyme of the 12-hour Daseulgi extract. In addition, Figure 3 is a graph showing the content of leucine among the amino acids shown in [Table 2].
[표 1], [표 2], 도 2 및 도 3의 결과는 예비실험으로 Alcalase, Flavourzyme, Neutrase, Alcalase+Flavourzyme, Alcalase+Neutrase, Flavourzyme+Neutrase, Alcalase+Flavourzyme+Neutrase 등 활용하여 다슬기 12시간 추출물을 분해한 결과를 분석한 결과, Leucine 분석치가 대조구는 0.1060, 효소별로는 2.5450, 2.6154, 3.0908, 5.1762, 4.9542, 4.7929, 6.1277mg/ml로 효소를 병행하여 분해한 결과가 가장 좋음을 확인할 수 있다. The results of [Table 1], [Table 2], Figures 2 and 3 are preliminary experiments, and Alcalase, Flavourzyme, Neutrase, Alcalase + Flavourzyme, Alcalase + Neutrase, Flavourzyme + Neutrase, Alcalase + Flavourzyme + Neutrase, etc. As a result of analyzing the result of decomposition of the extract, it can be seen that the Leucine analysis value is 0.1060 for the control and 2.5450, 2.6154, 3.0908, 5.1762, 4.9542, 4.7929, 6.1277mg/ml for each enzyme, confirming that the result of decomposing the enzyme in parallel is the best. .
총 아미노산 함량도 Alcalase+Flavourzyme+Neutrase 세가지 병행효소를 활용한 것이 41.9717mg/ml로 가장 높게 나왔는데, 이는 효소별로 각기 분해하는 지점이 달라 효소를 병행하여 분해하는 것이 최적의 분해 조건이라고 판단된다. The total amino acid content was also highest at 41.9717mg/ml using the three parallel enzymes Alcalase+Flavourzyme+Neutrace.
(Alcalase) 2.4LAlcalase
(Alcalase) 2.4L
(Flavourzyme) 500MGflavozyme
(Flavourzyme) 500MG
(Neutrase) 0.8Lneutrase
(Neutrace) 0.8L
(Alcalase) 2.4L +
플라보자임
(Flavourzyme) 500MGAlcalase
(Alcalase) 2.4L +
flavozyme
(Flavourzyme) 500MG
(Alcalase) 2.4L +
뉴트라제
(Neutrase) 0.8LAlcalase
(Alcalase) 2.4L +
neutrase
(Neutrace) 0.8L
(Flavourzyme)
500MG +
뉴트라제
(Neutrase) 0.8Lflavozyme
(Flavourzyme)
500MG+
neutrase
(Neutrace) 0.8L
(Alcalase) 2.4L
+ 플라보자임
(Flavourzyme) 500MG + 뉴트라제
(Neutrase) 0.8LAlcalase
(Alcalase) 2.4L
+ Flavozyme
(Flavourzyme) 500MG + Nutraze
(Neutrace) 0.8L
아래는 앞서 기술한 아미노산 함량 실험방법을 이용하여 나) 분쇄 다슬기와 슬러지의 용매 차이에 따른 아미노산 성분 분석 결과를 나타내었다. The following shows the results of analysis of amino acid components according to the difference between the solvents of b) the crushed crusher and the sludge using the amino acid content test method described above.
[표 3]은 분쇄다슬기의 용매별, 효소 함량별 아미노산함량(mg/mL) 결과이다. 또한, 도 4는 [표 3]에 아미노산 중 류신의 함량을 그래프로 나타내었다. [Table 3] shows the results of amino acid content (mg/mL) for each solvent and enzyme content of the crusher. In addition, FIG. 4 graphically shows the content of leucine among amino acids in [Table 3].
[표 4]는 분쇄다슬기 슬러지의 용매별, 효소 함량별 아미노산함량(mg/mL) 결과이다. 또한, 도 5은 [표 4]에 나타난 아미노산 중 류신의 함량을 그래프로 나타내었다. [Table 4] shows the results of amino acid content (mg/mL) for each solvent and enzyme content of the crushed sludge. In addition, Figure 5 is a graph showing the content of leucine among the amino acids shown in [Table 4].
[표 3], [표 4], 도 4 및 도 5는 다슬기를 분쇄하여 효소를 처리하였을 때 다슬기의 표면적이 높아 효소분해가 잘 될 수 있을 것이란 생각에서 분해를 한 결과인데, 효소는 세가지 병행 효소를 0.5%, 1.0% 비율로 사용하여 분쇄다슬기+녹차추출물, 분쇄다슬기+녹차잎차+정제수의 두 가지 조건으로 분해하였을 때 Leucine함량은 3.484, 3.951, 3.252, 2.953mg/ml의 결과가 나왔으며, 다슬기를 분해 후 여과지에 남은 슬러지를 사용하여 분해하였을 때, Leucine함량은 3.455, 3.834, 3.215, 1.268mg/ml의 결과가 나왔는데, 분쇄하지 않은 다슬기의 Leucine함량이 더 높게 나왔음을 확인할 수 있다. [Table 3], [Table 4], and Figures 4 and 5 are the results of decomposition in the idea that the enzyme decomposition would be good due to the high surface area of the dandelion group when the enzyme was pulverized. When the enzyme was decomposed under the two conditions of crushed crushed chives + green tea extract, crushed daisy + green tea leaf tea + purified water using enzymes at 0.5% and 1.0% ratios, the leucine content was 3.484, 3.951, 3.252, and 2.953 mg/ml. , when decomposed using the sludge remaining on the filter paper after decomposition of the sageum, the leucine content was 3.455, 3.834, 3.215, and 1.268mg/ml.
아래는 앞서 기술한 아미노산 함량 실험방법을 이용하여 다) 다슬기 추출 방법 선정 결과를 나타내었다. Below, using the amino acid content test method described above, the results of c) extraction method selection are shown.
[표 5]은 다슬기 12시간 추출물의 효소 함량별 아미노산함량(mg/mL) 결과이다. 또한, 도 6는 [표 5]에 아미노산 중 류신의 함량을 그래프로 나타내었다. [Table 5] shows the results of amino acid content (mg/mL) for each enzyme content of the 12-hour extract of Daseulgi. In addition, FIG. 6 graphically shows the content of leucine among amino acids in [Table 5].
[표 6]는 다슬기 24시간 추출물의 효소 함량별 아미노산함량(mg/mL) 결과이다. 또한, 도 7은 [표 6]에 나타난 아미노산 중 류신의 함량을 그래프로 나타내었다. [Table 6] shows the results of the amino acid content (mg/mL) by enzyme content of the 24 hour extract of Daseulgi. In addition, FIG. 7 graphically shows the content of leucine among the amino acids shown in [Table 6].
[표 5], [표 6], 도 6 및 도 7은 다슬기에 녹차추출물 1%를 혼합하고 Alcalase+Flavourzyme+Neutrase 세가지 병행효소를 각 1%, 2%, 3%의 비율로 혼합하고 12, 24시간동안 추출 및 분해하여 실험한 결과인데, Leucine함량은 12시간 샘플은 8.883(1%), 8.812(2%), 9.390(3%)mg/ml, 24시간 샘플은 9.482(1%), 9.800(2%), 7.716(3%)mg/ml로 결과가 높게 나왔음을 확인할 수 있다. [Table 5], [Table 6], Figures 6 and 7 show that 1% of green tea extract is mixed with Daseulgi, and Alcalase + Flavorzyme + Neutrase three parallel enzymes are mixed at a ratio of 1%, 2%, and 3%, respectively, 12, It is the result of extraction and decomposition for 24 hours, and the leucine content is 8.883 (1%), 8.812 (2%), 9.390 (3%) mg/ml for the 12-hour sample, 9.482 (1%) for the 24-hour sample, It can be seen that the results were high at 9.800 (2%) and 7.716 (3%) mg/ml.
사용량enzyme
usage
사용량enzyme
사용량enzyme
usage
사용량enzyme
usage
사용량enzyme
사용량enzyme
usage
결론적으로, 본 실험에서 추출시간은 12시간 및 24시간으로 추출하였고, 효소첨가량도 1%, 2%, 3%로 달리 첨가하여 분해하였을 때 대량생산을 위한 생산원가 등을 고려한다면 12시간 추출 및 1%의 효소첨가량이 최적 공정으로 적절하다고 판단할 수 있다. In conclusion, in this experiment, extraction time was 12 hours and 24 hours, and if the production cost for mass production is taken into consideration when the enzyme addition amount is also added and decomposed differently at 1%, 2%, 3%, 12 hours of extraction and It can be determined that an enzyme addition amount of 1% is appropriate for the optimal process.
아래는 앞서 기술한 다슬기 녹차겔, 영양성분 분석 실험방법을 이용하여 본 발명에 의해 제조된 다슬기 녹차겔의 영양성분을 [표 7]에 나타내었다. 본 발명에 의해 제조된 시제품인 다슬기 녹차겔을 ㈜한결분석센터에 영양성분 분석을 의뢰하였다.[Table 7] below shows the nutritional components of Daseulgi green tea gel prepared by the present invention using the above-described test method for analyzing nutrient components. Daseulgi Green Tea Gel, a prototype manufactured by the present invention, was requested to be analyzed for nutritional components by the Hangyeol Analysis Center.
(100g당 함량)Analysis
(content per 100g)
의한 결과how to display
result by
아래는 앞서 기술한 다슬기 녹차겔 미량원소 분석 실험방법을 이용하여 본 발명에 의해 제조된 다슬기 녹차겔의 시간 및 효소별 추출물의 미량원소 함량(mg/kg) 분석결과를 [표 8]에 나타내었다. 본 발명에 의해 제조된 시제품인 다슬기 녹차겔을 효소 함량 1%, 2%, 3%에 따른 다슬기 추출물(12시간, 24시간 추출) 분말과 시제품인 다슬기 녹차겔을 미량원소 분석하였다.[Table 8] shows the results of analysis of the trace element content (mg/kg) of the extract for each time and enzyme of the green tea gel prepared by the present invention using the above-described test method for analyzing the trace elements of Daseulgi green tea gel. . Daseulgi green tea gel, a prototype manufactured by the present invention, was analyzed for trace elements on the extract of Daseulgi extract (12 hours, 24 hours) powder according to the enzyme content of 1%, 2%, and 3%, and the prototype Daseulgi green tea gel.
다슬기 시간 및 효소별 추출물의 아미노산 함량은 [표 3 내지 6]에 나타내었다. 효소의 첨가량이 많아질수록 나트륨 함량이 높았으며 12hr 보다는 24hr 추출 하였을 때 나트륨이 함량이 높아 유의적인 차이를 나타내었다. The amino acid content of the extract for each enzyme time and enzyme is shown in [Tables 3 to 6]. As the amount of enzyme added increased, the sodium content was higher, and the sodium content was higher when the extraction was performed for 24 hr than for 12 hr, indicating a significant difference.
칼슘 함량은 근육, 신경 기능 조절, 혈액 응고에 도움이 되는 칼슘의 경우 효소 첨가량이 많아질수록 칼슘의 함량은 낮아 졌으며 12hr 보다는 24hr의 칼슘 함량이 높은 것으로 나타났다.As for the calcium content, as for calcium, which is helpful for muscle and nerve function control and blood coagulation, the higher the amount of enzyme added, the lower the calcium content.
몸속의 노폐물 처리에 도움이 칼륨의 경우 효소 첨가량에 따라 큰 차이를 나타내지 않았으며 12hr과 24hr 추출에 대해서도 큰 차이를 나타내지 않았다. In the case of potassium, which helps in the treatment of wastes in the body, there was no significant difference depending on the amount of enzyme added, and there was no significant difference between 12hr and 24hr extraction.
철의 함량은 효소 첨가량이 많을수록 철의 함량은 1% → 2% (43% 감소) 2% → 3% (48% 감소) 큰 폭으로 감소 하였다.As for the iron content, as the amount of enzyme added increased, the iron content decreased significantly by 1% → 2% (43% decrease) 2% → 3% (48% decrease).
인의 함량은 효소 첨가량이 많을수록 인의 함량은 1%에 비해 2% 약 40% 감소하였고 2%에 비해 3%는 31% 감소하였다. 12hr, 24hr 추출에 대해서도 감소하는 경향을 보여 유의적인 차이를 나타내었다. As for the phosphorus content, as the amount of enzyme added increased, the phosphorus content decreased by 2% compared to 1% by 40%, and by 3% compared to 2% decreased by 31%. 12hr and 24hr extraction also showed a decreasing trend, indicating a significant difference.
아래는 앞서 기술한 다슬기 녹차겔 미량원소 분석 실험방법을 이용하여 본 발명에 의해 제조된 다슬기 녹차겔의 미량원소 분석(mg/kg) 결과를 [표 9]에 나타내었다. [Table 9] shows the results of trace element analysis (mg/kg) of Daseulgi green tea gel prepared by the present invention using the aforementioned experimental method for analysis of trace elements in Daseulgi green tea gel.
(ug/mL)density
(ug/mL)
(g)sample volume
(g)
(mL)Volume
(mL)
배수dilution
Drainage
(mg/kg)calculated value
(mg/kg)
(mg/kg)notation value
(mg/kg)
녹차겔shredded
green tea gel
칼슘은 438.3 mg/kg, 인 83.3 mg/kg, 철 0.4 mg/kg, 나트륨 65.9 mg/kg, 칼륨 704.9 mg/kg을 나타내어 칼륨과 칼슘 함량이 높게 나타내었다. Calcium was 438.3 mg/kg, phosphorus 83.3 mg/kg, iron 0.4 mg/kg, sodium 65.9 mg/kg, and potassium 704.9 mg/kg, indicating high potassium and calcium contents.
아래는 본 발명에 의해 제조된 실시예 및 비교예를 이용하여 실시한 관능검사 결과를 나타내고자 한다. The following is to show the results of the sensory test conducted using the Examples and Comparative Examples prepared by the present invention.
본 검사는 주식회사 정옥에서 고령친화식품으로 개발한 레토르트 겔 1종의 소비자 기호도를 알아보기 위하여 실시하였다.This test was conducted to determine the consumer preference for one type of retort gel developed by Jeongok Co., Ltd. as an age-friendly food.
본 검사에 참여한 40~50대 여성패널 15명은 주식회사 식품환경연구센터에서 모집하였으며, 관능검사 이전에 평가 방법에 대하여 교육한 후 10명씩 관능검사 부스에서 평가를 진행하였다. 관능검사에 사용한 제품은 아래의 [도 8(A)]과 같다. 제품은 제공하기 전 전자렌지에 2분간 조리한 후 따뜻한 상태로 [도 8(B)]와 같이 제공하였으며, 세 자리 난수표를 이용하여 표기하였다.Fifteen female panelists in their 40s and 50s who participated in this test were recruited from the Food Environment Research Center, Inc., and were educated on the evaluation method before the sensory test, and then evaluated at the sensory test booth by 10 people. The product used for the sensory test is shown in [Fig. 8(A)] below. The product was cooked in a microwave for 2 minutes before being provided and then provided in a warm state as shown in [FIG. 8(B)], and marked using a three-digit random number table.
관능검사는 7점 척도법을 사용하여 진행하였다. 기호도 평가속성은 ‘외관’, ‘색감’, ‘짠맛’, ‘비린맛’, ‘식감’, ‘후미’, ‘전체적인 기호도’에 대하여 검사하였으며, 정도 평가속성은 ‘색감’, ‘짠맛’, ‘비린맛’, ‘식감’, ‘후미’에 대하여 검사하였다. 기호도는 1점 ‘대단히 싫다’, 2점 ‘싫다’, 3점 ‘조금 싫다’, 4점 ‘보통이다’, 5점 ‘조금 좋다’, 6점 ‘좋다’, 7점 ‘대단히 좋다’로 평가하였다. 정도는 1점 ‘대단히 연하(약하/무르)다’, 2점 ‘연하(약하/무르)다’, 3점 ‘약간 연하(약하/무르)다’, 4점 ‘연하(약하/무르)지도 진(강/단단)하지도 않다’, 5점 ‘약간 진(강/단단)하다’, 6점 ‘진(강/단단)하다’, 7점 ‘대단히 진(강/단단)하다’로 평가하였다. 검사 중 패널간의 소통을 금하게 하여 객관적인 평가를 할 수 있도록 하였으며, 충분한 시간 동안 시료를 평가할 수 있게 하였다.The sensory test was conducted using the 7-point scale method. Preference evaluation attributes were examined for 'appearance', 'color', 'salty', 'fishy taste', 'texture', 'taste', and 'total preference'. The 'fishy taste', 'texture' and 'taste' were examined. The degree of preference was evaluated as 1 point 'dislike', 2 points 'dislike', 3 points 'a little dislike', 4 points 'average', 5 points 'somewhat good', 6 points 'like', 7 points 'very good'. did. The degree of degree is 1 point 'very soft (soft/soft)', 2 points 'soft (weak/soft)', 3 points 'slightly soft (weak/soft)', 4 points 'soft (soft/soft) guidance Not too strong (strong/hard)', 5 points 'slightly strong (strong/hard)', 6 points 'strong (strong/hard)', 7 points 'very strong (strong/hard)' . By prohibiting communication between the panels during the examination, it was possible to make an objective evaluation, and to evaluate the sample for a sufficient time.
*764 : 레토르트 겔, 값 : 평균±표준편차, n=15*764: retort gel, value: mean±standard deviation, n=15
[표 10]는 40~50대 여성패널 15명을 대상으로 진행한 레토르트 겔의 속성별 기호도를 나타낸 결과이다. 본 제품의 외관, 색감, 식감, 후미, 전체적인 기호도는 4.73점, 4.40점, 4.67점, 4.20점, 4.0점으로 ‘보통이다’로 평가되었다. 짠맛, 비린맛의 기호도는 3.40점, 3.47점으로 ‘조금 싫다’로 평가되었다. 아래의 [도 9]는 40~50대 여성패널 15명을 대상으로 레토르트 겔의 관능검사 결과 중 각 속성별 기호도를 나타낸 결과 그래프이다.[Table 10] shows the results showing the preference for each attribute of the retort gel conducted for 15 female panelists in their 40s and 50s. The appearance, color, texture, aftertaste, and overall preference of this product were evaluated as ‘normal’ with 4.73 points, 4.40 points, 4.67 points, 4.20 points, and 4.0 points. The preference for salty and fishy taste was evaluated as 'a little dislike' with 3.40 and 3.47 points. [Fig. 9] below is a graph showing the preference for each attribute among the sensory test results of the retort gel for 15 female panelists in their 40s and 50s.
*764 : 레토르트 겔, 값 : 평균±표준편차, n=15*764: retort gel, value: mean±standard deviation, n=15
[표 11]은 40~50대 여성패널 15명을 대상으로 진행한 레토르트 겔의 특성별 정도를 나타낸 결과이다. 본 제품의 색감, 짠맛, 비린맛, 후미의 정도는 4.87점, 4.93점, 4.73점, 4.47점으로 연(약)하지도 진(강)하지도 않다’로 평가되었으며, 식감의 정도는 3.80점으로 ‘약간 무르다’로 평가되었다. 아래의 [도 10]은 40~50대 여성패널 15명을 대상으로 레토르트 겔의 관능검사 결과 중 각 속성별 정도를 나타낸 결과 그래프이다.[Table 11] shows the results showing the degree of each characteristic of the retort gel conducted for 15 female panelists in their 40s and 50s. The degree of color, saltiness, fishy taste, and aftertaste of this product was evaluated as 'not mild (weak) or strong (strong)' with 4.87, 4.93, 4.73, and 4.47 points, and the degree of texture was ' 3.80 points. It was evaluated as 'slightly soft'. [Fig. 10] below is a graph showing the degree of each attribute among the sensory test results of the retort gel for 15 female panelists in their 40s and 50s.
결론적으로, 40~50대 여성패널 15명을 대상으로 진행한 레토르트 겔 제품은 짠맛과 비린맛을 제외한 모든 항목은 4.00점 이상으로 ‘보통이다’로 평가되었다. 짠맛과 비린맛의 정도는 각각 4.93점, 4.73점으로 ‘약하지도 강하지도 않다’로 평가되었지만, 기호도가 3.40점, 3.47점으로 평가되어 짠맛과 비린맛의 정도를 낮출 필요가 있는 것으로 판단된다. 비린맛의 경우 후미에서는 큰 영향을 주지 않는 것으로 판단되는데, 이는 후미의 정도가 4.47점으로 비린맛의 정도가 큰 차이가 없지만, 기호도에선 4.20점으로 ‘보통이다’로 평가되었기 때문이다. 따라서 비린맛의 경우는 제품을 섭취하기 전 나타나는 비린맛에 대하여 개선할 필요가 있는 것으로 판단된다. 7점 척도법으로 관능검사를 진행한 경우 5.0점 이상을 ‘조금 좋다’로 평가하는데, 레토르트 겔의 관능검사 결과 전체적인 기호도가 4.0점으로 ‘보통이다’로 평가되었다. 본 제품의 기호도를 높이기 위해 짠맛과 비린맛에 대하여 개선할 필요가 있는 것으로 판단된다.In conclusion, the retort gel product, conducted with 15 female panelists in their 40s and 50s, was evaluated as 'normal' with a score of 4.00 or higher except for salty and fishy taste. The degree of salty taste and fishy taste was evaluated as ‘not weak or strong’ with 4.93 and 4.73 points, respectively, but the preference was evaluated at 3.40 and 3.47 points, indicating that it is necessary to lower the degree of salty and fishy taste. In the case of fishy taste, it is judged not to have a significant effect on the aftertaste, because the degree of the aftertaste was 4.47 points, which showed no significant difference in the degree of fishy taste. Therefore, in the case of fishy taste, it is judged that it is necessary to improve the fishy taste that appears before ingesting the product. When the sensory test was conducted using the 7-point scale method, a score of 5.0 or higher was evaluated as ‘slightly good’. It is judged that it is necessary to improve the salty and fishy taste in order to increase the preference of this product.
상기 과제의 해결 수단에 의해, 본 발명은 다슬기와 녹차의 유효성분을 추출하는 효과적인 방법을 제시할 수 있다. By means of solving the above problems, the present invention can present an effective method of extracting the active ingredient of green tea leaves.
또한, 본 발명은 다슬기와 녹차에서 추출된 추출물을 이용하여 노인을 위한 식품에 응용할 수 있는 유효 추출물을 제공할 수 있다. In addition, the present invention can provide an effective extract that can be applied to food for the elderly by using the extract extracted from Daseulgi and green tea.
또한, 본 발명은 다슬기와 녹차의 혼합물에서 아미노산의 함량을 증가시킬 수 있는 추출방법을 제공할 수 있다. In addition, the present invention can provide an extraction method capable of increasing the content of amino acids in a mixture of green tea and dandelion.
또한, 본 발명은 근감소증 개선을 위해 근관세포(myotube) 분화, 근육 단백질 성장 억제인자(Myostatin) 감소 및 근육 세포 특이 효소인 류신의 활성을 증가시킬 수 있는 추출물을 제공할 수 있다. In addition, the present invention can provide an extract capable of increasing myotube differentiation, reduction of muscle protein growth inhibitory factor (Myostatin), and activity of muscle cell-specific enzyme leucine for improving sarcopenia.
이와 같이, 상술한 본 발명의 기술적 구성은 본 발명이 속하는 기술분야의 당업자가 본 발명의 그 기술적 사상이나 필수적 특징을 변경하지 않고서 다른 구체적인 형태로 실시될 수 있다는 것을 이해할 수 있을 것이다.As such, those skilled in the art to which the present invention pertains will understand that the above-described technical configuration of the present invention may be implemented in other specific forms without changing the technical spirit or essential characteristics of the present invention.
그러므로 이상에서 기술한 실시예들은 모든 면에서 예시적인 것이며 한정적인 것이 아닌 것으로서 이해되어야 하고, 본 발명의 범위는 상기 상세한 설명보다는 후술하는 특허청구범위에 의하여 나타나며, 특허청구범위의 의미 및 범위 그리고 그 등가 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.Therefore, the embodiments described above are to be understood as illustrative and not restrictive in all respects, and the scope of the present invention is indicated by the following claims rather than the above detailed description, and the meaning and scope of the claims and their All changes or modifications derived from the concept of equivalents should be construed as being included in the scope of the present invention.
S100. 정제수 70중량%, 칡 10중량%, 헛개줄기 10중량%, 헛개열매 5중량% 및 천궁5 중량%를 혼합하여 혼합식물추출액을 제조하는 제1단계
S200. 다슬기 과육, 증류수 및 녹차추출물을 혼합하여 농축다슬기녹차추출액을 제조하는 제2단계
S210. 상기 다슬기 과육, 증류수, 녹차추출물을 혼합한 혼합물에 알칼라아제(Alcalase), 플라보자임(Flavourzyme) 및 뉴트라제(Neutrase) 효소을 혼합하는 제2-1단계
S220. 상기 효소가 혼합된 혼합물을 진탕배양기(shaking incubator)에서 추출하는 제2-2단계
S230. 상기 추출된 혼합물을 거름망으로 여과하는 제2-3단계
S240. 감압농축기로 30℃에서 40rpm 이하 및 30mbar 압력으로 농축하는 제2-4단계
S250. 100hPa 이하의 압력 및 -70℃ 이하의 온도로 동결건조하는 제2-5단계
S300. 카라기난 57.25중량%에 정제염 0.1중량%를 혼합하는 제3단계
S400. 상기 카라기난과 정제염 혼합물에 올리고당 15중량%, 상기 혼합식물추출액 15중량%, 상기 농축다슬기녹차추출액 12중량%, 비타민C 0.2중량%, 엽산 0.1중량%, 젖산칼슘 0.1중량% 및 구연산 0.05중량%를 혼합하는 제4단계
S500. 상기 제4단계에서 혼합된 혼합물을 100℃에서 20분 동안 가열하여 다슬기녹차겔을 제조하는 제5단계
S600. 상기 다슬기녹차겔을 용기에 넣고 밀봉 포장하는 제6단계
S700. 상기 밀봉 포장된 다슬기녹차겔을 멸균하는 제7단계S100. The first step of preparing a mixed plant extract by mixing 70% by weight of purified water, 10% by weight of arrowroot, 10% by weight of hutgae stem, 5% by weight of hutgae fruit, and 5% by weight of cheongung
S200. The second step of preparing a concentrated green tea extract solution by mixing the pulp of dried sageum, distilled water, and green tea extract
S210. Step 2-1 of mixing Alcalase, Flavozyme, and Neutrase enzymes in a mixture of the dried sageum pulp, distilled water, and green tea extract
S220. Step 2-2 extracting the mixture in which the enzyme is mixed in a shaking incubator
S230. Step 2-3 of filtering the extracted mixture through a sieve
S240. Step 2-4 concentrating at 30 ℃ with a reduced pressure concentrator at 40 rpm or less and a pressure of 30 mbar
S250. Step 2-5 of freeze-drying at a pressure of 100 hPa or less and a temperature of -70 ° C or less
S300. Third step of mixing 0.1% by weight of refined salt with 57.25% by weight of carrageenan
S400. To the carrageenan and refined salt mixture, 15% by weight of oligosaccharide, 15% by weight of the mixed plant extract, 12% by weight of the concentrated green tea extract, 0.2% by weight of vitamin C, 0.1% by weight of folic acid, 0.1% by weight of calcium lactate and 0.05% by weight of citric acid 4th step of mixing
S500. A fifth step of preparing the green tea gel by heating the mixture mixed in the fourth step at 100° C. for 20 minutes
S600.
S700. The seventh step of sterilizing the sealed-packaged Daseulgi green tea gel
Claims (5)
다슬기 과육, 증류수 및 녹차추출물을 혼합하여 농축다슬기녹차추출액을 제조하는 제2단계;
카라기난 57.25중량%에 정제염 0.1중량%를 혼합하는 제3단계;
상기 카라기난과 정제염 혼합물에 올리고당 15중량%, 상기 혼합식물추출액 15 중량%, 상기 농축다슬기녹차추출액 12중량%, 비타민C 0.2중량%, 엽산 0.1중량%, 젖산칼슘 0.1중량% 및 구연산 0.05중량%를 혼합하는 제4단계;
상기 제4단계에서 혼합된 혼합물을 100℃에서 20분 동안 가열하여 다슬기녹차겔을 제조하는 제5단계;
상기 다슬기녹차겔을 용기에 넣고 밀봉 포장하는 제6단계;
상기 밀봉 포장된 다슬기녹차겔을 멸균하는 제7단계;를 통해 제조되는 것을 특징으로 하는 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔 제조 방법.
A first step of preparing a mixed plant extract by mixing 70% by weight of purified water, 10% by weight of arrowroot, 10% by weight of hutgae stem, 5% by weight of hutgae fruit, and 5% by weight of cheongung;
A second step of preparing a concentrated green tea extract of dandelion extract by mixing the pulp of dandelion, distilled water, and green tea extract;
A third step of mixing 0.1% by weight of purified salt with 57.25% by weight of carrageenan;
To the carrageenan and refined salt mixture, 15% by weight of oligosaccharide, 15% by weight of the mixed plant extract, 12% by weight of the concentrated green tea extract, 0.2% by weight of vitamin C, 0.1% by weight of folic acid, 0.1% by weight of calcium lactate and 0.05% by weight of citric acid a fourth step of mixing;
a fifth step of heating the mixture mixed in the fourth step at 100° C. for 20 minutes to prepare a green tea gel;
a sixth step of putting the dried green tea gel into a container and sealingly packaging;
An aging-friendly green tea gel manufacturing method using an enzyme decomposed product of Daseulgi Daseulgi and a green tea extract, characterized in that it is prepared through the seventh step of sterilizing the sealed and packaged Daseulgi green tea gel.
상기 농축다슬기녹차추출액은,
상기 다슬기 과육 80중량%에 대하여 증류수 17중량%, 녹차추출물 3중량%를 혼합한 혼합물에 효소혼합물을 혼합하는 제2-1단계;
상기 효소혼합물이 혼합된 혼합물을 진탕배양기(shaking incubator)에서 추출하는 제2-2단계;
상기 추출된 혼합물을 거름망으로 여과하는 제2-3단계;
감압농축기로 30℃에서 40rpm 이하 및 30mbar 압력으로 농축하는 제2-4단계;
90hPa 내지 100hPa의 압력 및 -80℃ 내지 -70℃의 온도로 동결건조하는 제2-5단계;를 통해 제조하되,
상기 효소혼합물은 뉴트라제(Neutrase) 1 중량부에 대하여 알칼라아제(Alcalase) 1 중량부 및 플라보자임(Flavourzyme) 1 중량부를 혼합하는 것을 특징으로 하는 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔 제조 방법.
The method of claim 1,
The concentrated Daseulgi green tea extract,
Step 2-1 of mixing the enzyme mixture with the mixture of distilled water 17% by weight and green tea extract 3% by weight based on 80% by weight of the pulp;
Step 2-2 of extracting the mixture in which the enzyme mixture is mixed in a shaking incubator;
Step 2-3 of filtering the extracted mixture through a sieve;
Step 2-4 of concentrating with a vacuum concentrator at 30° C. at 40 rpm or less and at a pressure of 30 mbar;
Prepared through; step 2-5 of freeze-drying at a pressure of 90 hPa to 100 hPa and a temperature of -80 °C to -70 °C;
The enzyme mixture is an aging-friendly Daseulgi using an enzyme decomposition product of Daseulgi and green tea extract, characterized in that 1 part by weight of Alcalase and 1 part by weight of Flavozyme are mixed with respect to 1 part by weight of Neutrase. How to make green tea gel.
상기 효소혼합물은,
상기 농축다슬기녹차추출액 1중량부에 대하여 상기 뉴트라제(Neutrase), 알칼라아제(Alcalase) 및 플라보자임(Flavourzyme) 각각 0.3 중량부 혼합하는 것을 특징으로 하는 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔 제조 방법.
3. The method of claim 2,
The enzyme mixture is
Aging-friendly using an enzyme decomposition product of Daseulgi and green tea extract, characterized in that 0.3 parts by weight of each of the Neutrase, Alcalase and Flavozyme is mixed with respect to 1 part by weight of the concentrated Daseulgi green tea extract Daseulgi Green Tea Gel Manufacturing Method.
상기 제2단계에서 농축다슬기녹차추출액은,
뉴트라제(Neutrase), 알칼라아제(Alcalase) 및 플라보자임(Flavourzyme)을 혼합한 효소혼합물을 추가하는 것을 특징으로 하는 다슬기 효소 분해물 및 녹차 추출물을 이용한 고령친화 다슬기 녹차 겔 제조 방법.
The method of claim 1,
In the second step, the concentrated green tea extract
A method for preparing an aging-friendly green tea gel using an enzyme decomposition product of dandelion and green tea extract, characterized in that adding an enzyme mixture mixed with neutrase, alcalase, and flavozyme.
5. Aging-friendly green tea gel using the enzyme decomposition product and green tea extract of Daseulgi, which is prepared by the method of any one of claims 1 to 4.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200014098A KR102472794B1 (en) | 2020-02-06 | 2020-02-06 | Manufacturing method for gel effective components in melania snail and green tea for development of senior-friendly food |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020200014098A KR102472794B1 (en) | 2020-02-06 | 2020-02-06 | Manufacturing method for gel effective components in melania snail and green tea for development of senior-friendly food |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210100768A true KR20210100768A (en) | 2021-08-18 |
KR102472794B1 KR102472794B1 (en) | 2022-12-02 |
Family
ID=77464563
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020200014098A KR102472794B1 (en) | 2020-02-06 | 2020-02-06 | Manufacturing method for gel effective components in melania snail and green tea for development of senior-friendly food |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102472794B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102642096B1 (en) * | 2022-12-30 | 2024-03-04 | (주)팜설레임 농업회사법인 | How to grow vegetables or grains using green tea |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4263513B2 (en) | 2003-03-20 | 2009-05-13 | 三栄源エフ・エフ・アイ株式会社 | Mastication / swallowing foods and chewing / swallowing assist compositions |
KR20130006275A (en) * | 2011-07-07 | 2013-01-16 | 추호진 | Method for manufacturing melanian snail extract and functional food having the extract |
KR20160068171A (en) * | 2014-12-05 | 2016-06-15 | 추호진 | A Snail Liquid Manufacturing Method |
-
2020
- 2020-02-06 KR KR1020200014098A patent/KR102472794B1/en active IP Right Grant
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4263513B2 (en) | 2003-03-20 | 2009-05-13 | 三栄源エフ・エフ・アイ株式会社 | Mastication / swallowing foods and chewing / swallowing assist compositions |
KR20130006275A (en) * | 2011-07-07 | 2013-01-16 | 추호진 | Method for manufacturing melanian snail extract and functional food having the extract |
KR20160068171A (en) * | 2014-12-05 | 2016-06-15 | 추호진 | A Snail Liquid Manufacturing Method |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102642096B1 (en) * | 2022-12-30 | 2024-03-04 | (주)팜설레임 농업회사법인 | How to grow vegetables or grains using green tea |
Also Published As
Publication number | Publication date |
---|---|
KR102472794B1 (en) | 2022-12-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101301094B1 (en) | Composition for relieving hangover or improving liver function | |
KR100685745B1 (en) | Method for processing a functional sprout beverage and product thereof | |
KR20130029098A (en) | Mathod for manufacturing ion mineral using silk worm, muberry leaf, and muberry twig and health drink manufactured by this | |
CN101238904B (en) | Chickpea bean sprout juice tea and preparation method and application | |
CN112772813A (en) | Compound peptide solid beverage capable of improving immunity and relieving fatigue and preparation method thereof | |
KR20090032562A (en) | Functional drink comprising abalone extract and the preparation method of thereof | |
CN106376917A (en) | Health food or drink formula for regulating emotions from multiple aspects | |
KR20170024321A (en) | The process of making healthcare compositions comprising fermented Dendropanax morbifera extracts and herbal medicines Abalone extracts | |
WO2019203136A1 (en) | Food composition for improving cognitive function, cognitive function improvement agent, and production method thereof | |
CN102048225A (en) | Red-date health protection beverage capable of improving growing development | |
CN101380128B (en) | Zhukui multifunctional health care beverage and production method thereof | |
KR102472794B1 (en) | Manufacturing method for gel effective components in melania snail and green tea for development of senior-friendly food | |
KR102341885B1 (en) | A natural tea removing the effect of hangover contained the extract material in Hovenia dulcis and a cactus | |
KR102472789B1 (en) | Manufacturing method for porridge effective components in melania snail and green tea for development of senior-friendly food | |
KR20100114974A (en) | A functional beverage comprising deep sea water, extract of black garlic, extract of jujubae fructus and organic acid | |
KR102428634B1 (en) | Manufacturing method of grub granule | |
CN101715958A (en) | Method for preparing honey-olive paste | |
JP3762364B2 (en) | Health food production method using earthworms and ants | |
KR101773250B1 (en) | The manufacturing method of making healthcare compositions comprising fermented Eriobotrya japonica extracts and herbal medicines Abalone extracts | |
KR102480311B1 (en) | The manufacturing method of making healthcare food composition for costitutional group | |
KR20080039135A (en) | Anti-hypertensive beverage composition comprising acanthopanax senticosus and process for preparing the same | |
KR20140000464A (en) | Healthy and functional food for improving concentration or growth by using fermented natural products and the manufacturing method | |
KR20210041387A (en) | A natural tea removing the effect of hangover contained the extract material in arrowroot blossoms and Plantago ovata | |
KR101706954B1 (en) | Method for manufacturing a seasoning crab | |
KR20210002221A (en) | Red ginseng products containing noni and the process for the preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |